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61 Introduction
1.1 Overactive Bladder
Overactive bladder (OAB) is urgency, with or without urge incontinence, with increased
frequency of voiding and nocturia. Symptoms of an OAB are highly prevalent in the
general population, which has a considerable impact on patients health-related quality of
life (Milson et al. 2001). The prevalence of OAB from population-based studies ranges
from 7% to 27% in men and 9% to 43% in women (Corcos and Schick 2004).
Like other chronic conditions, OAB requires long-term therapy. Behavioral modification
and training of pelvic floor muscle are safe and recommended treatment options for all
patients (Burgio et al. 1998). However, only 20 % of patients in clinical studies achieve
complete remission of their symptoms. For this case, pharmacotherapy is an important
adjunct. Antimuscarinic agents are commonly used first-line pharmacological therapy
(Guidelines of the European Association of Urology 2015). They block muscarinic
receptors in the bladder wall, reducing detrusor contractility and sensation. However, only
10-25% of patients continue their treatment after 12 months (Sexton et al. 2011). The
main reason is the adverse effects of antimuscarinic drugs such as dry mouth, dizziness,
constipation, and ocular hypertension. On the other hand, it seems as if the effect of
therapy does not satisfy the patients (Chapple 2000).
OAB is preferentially associated with the following conditions: aging, diabetes mellitus,
bladder outlet obstruction, interstitial cystitis, spinal cord and brain injury, stroke,
Parkinson’s disease, and multiple sclerosis. Still, the pathophysiology of OAB is not well
understood. The International Continence Society (ICS) assumes as underlying
pathological processes in the formation of OAB an increased afferent nerve activity and
mechanisms involved in the abnormal handling of afferent signals (Abrams et al. 2003).
The increased afferent activity can be explained by changes in urothelial receptor function
and neurotransmitter release, as well as by changes in the sensitivity and coupling of the
suburothelial myofibroblasts. Therefore, this state amplifies the sensation of bladder
fullness, leading to the urgency and predisposes the activation of the micturition reflex.
This is the urothelium based hypothesis. Another hypothesis is the myogenic hypothesis.
In the myogenic hypothesis, the involuntary contraction of the detrusor muscle is
7provoked by changes in myocyte excitability and coupling of myocytes with other
myocytes or myofibroblasts (Brading 1997, Chapple 2014).
The mechanisms involved in the abnormal handling of afferent signals originate from the
damage of central inhibitory pathways (de Groat 1997). The neural circuitry that
participates in this process is complex. Several recent findings support a key role for
purinergic transmission in overactive bladder. O’Reilly et al. reported that purinergic
P2X2 receptors were significantly increased in bladder tissue specimens obtained from
women with idiopathic OAB (O’Reilly et al. 2002). Additionally, substantially increased
nerve-mediated contraction due to ATP release were observed in these bladder samples.
The issue of the study was that there is an abnormal purinergic transmission in the bladder
of patients with idiopathic OAB, which can lead to the above-mentioned symptoms.
There is also increasing evidence that ATP mediated detrusor contraction increases with
age and plays an important role in bladder disorders such as OAB. Recent data also show
an age-related reduction in cholinergic transmission. However, the importance of these
changes in the pathophysiology of OAB is not clear. The future research of OAB should
be directed towards an in-depth understanding of the sensory, myogenic and motor
mechanisms and how they cooperate.
1.2 Anatomy of the lower urinary tract
The lower urinary tract (LUT) is composed of the bladder and urethra. Extensive
differences between males and females LUT concern the structure of bladder neck and
urethra. The characteristic features of the male urethra are the prostate gland in the
proximal portion of the urethra, and the longer distal portion due to its extension to the
urethral plate of the penis (Elbadawi et al. 1966).
The empty bladder has a tetrahedral form and a capacity of nearly 500 ml. Superiorly, the
bladder is covered by peritoneum. The anterior abdominal wall borders to the anterior
surface of the bladder. Posteriorly, the peritoneum extends to the seminal vesicles and
connects with the peritoneal sheet of the rectum to form the rectovesical space. In the
female, the bladder superiorly and posteriorly borders to the uterus and vagina, forming
the vesicouterine pouch. Inferiorly and laterally, the bladder is surrounded by the pelvic
sidewall.
8The bladder can be divided into a body, located above the ureter orifices, and a base
consisting of the trigone and bladder neck (Tanagho et al. 1982). Donker and colleagues
showed in their histologic examination that the myofibrils of the bladder body are
arranged into randomly directed fascicles and muscle layers are not separable (Donker et
al. 1976). This network of the detrusor muscle is ideally constructed for emptying the
bladder.
The trigonal part of the bladder base consists of three distinct muscle layers: a superficial
layer, derived from the longitudinal muscle of the ureter; a deep layer, which extends
from the fibromuscular (Waldeyer) sheath, and the detrusor muscle formed by
longitudinal and circular smooth muscle. As the ureter approaches the urinary bladder,
the mural smooth muscle fibers run longitudinal and obliquely pierce the bladder wall. In
the intercrossing of intramural ureter and detrusor, the ureter is compressed and forms a
physiological stricture. This intercrossing acts as a flap valve and provides the passive
closure of the ureter during bladder filling (Thompson et al. 1994).
Adjacent to the bladder neck, the detrusor muscle is separable into the above-mentioned
three layers, and it persists of many finer fibers. The middle layer shows structural
differences in male and female gender. In men, this is expressed in a competent and
circular ring-like smooth muscle, the internal urethral sphincter (Gosling et al. 1981). The
internal urethral sphincter is efficient to maintain continence in men, even if the striated
(external) urethral sphincter is damaged (Waterhouse et al. 1973). In contrast, in 50% of
continent women, urine enters the proximal urethra during coughing due to the absence
of circular smooth muscle (Versi et al. 1986). In addition, the closure of the bladder neck
in men promotes anterograde ejaculation. Sympathetic nerve fibers richly innervate the
bladder neck. Their activation leads to contraction of the bladder neck during ejaculation.
De Groat and Booth described in women a lower density of sympathetic nerves than in
men (De Groat and Booth 1993).
The urethra begins at the bladder outlet and expands to the external meatus. There are
four segments in the male urethra: preprostatic urethra, prostatic urethra, membranous
urethra, spongy urethra (bulbar and penile part). Circular smooth muscle from the bladder
neck extends to the preprostatic part of the urethra (Gosling et al. 1999). The length of
the preprostatic urethra varies from 0.5-1.5 cm.
The prostatic part extends through the length of the gland. The urethral crest builds a
verumontanum on the posterior wall. On the apex of the verumontanum, there is a
9Müllerian duct residue, the prostatic utricle. Ejaculatory ducts open from either side of
the utriculum.
The membranous urethra courses from the apex of the prostate to the perineal membrane.
The average length of the membranous part varies from 2-2.5 cm (1.2-5 cm) (Myers et
al. 1991). A striated external urethral sphincter is located in the membranous urethra. This
is an important structure to maintain continence. The external urethral sphincter has a
broad base and a narrowing at the apex of the prostate in the urogenital hiatus of the
levator ani.
In contrast to males, the female urethra is short and approximately 4 cm in length. Several
authors deny the existence of an internal urethral sphincter (Gosling et al. 1981, Lassmann
et al. 1984). However, the external urethral sphincter builds up two-thirds of the distal
urethra (Oelrich et al. 1983). The sphincter mechanism of females is divided into two
components. In the proximal part, it forms a complete ring around the urethra and distally
the fibers do not meet posteriorly, forming two arch-shaped straps of muscle (De Groat
and Yoshimura 2015). Contraction of the distal part leads to compression of the urethra
against the fixed anterior vaginal wall.
1.3 Bladder compartments
1.3.1 Urothelium
The urothelium is a multilayer epithelium that consists, depending on species, of up to
seven cell layers (Fawcett et al. 1984). There are three important layers (Fig.1.1): basal,
intermediate and apical (umbrella cells). Umbrella cells are the largest epithelial cells
covering the luminal surface of the urothelium (Lewis et al. 2000). The name “umbrella”
is given due to its shape. Each umbrella cell can cover several intermediate cells and can
reach the basal membrane with a stem-line process. Besides the primary urine-plasma
barrier function, umbrella cells can stretch during bladder filling. One of the explanations
of this phenomenon is a large number of discoid vesicles under the apical membrane.
While stretching the amount of vesicle decreases rapidly through exocytosis and leads to
an increase of the cell surface (Porter et al. 1967, Staehelin et al 1972, Sarikas and
Chlapowsky 1986).
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Figure 1.1 Diagrammatic representation of the bladder urothelium. The lumen of the
bladder is on top and the lamina propria is below.
One essential and highly discussed function of the urothelium is its barrier function. In
the seventies, Parsons and Mulholland assumed that the glucosaminoglycan (GAG) layer
plays an essential role in the barrier function of the urothelium. GAG is a polysaccharide,
which covers the luminal surface of umbrella cells. Their theory was based on increased
bacterial adherence in rabbit urothelium after topical acid instillation and recovery of
normal barrier function within 24 hours after injury, supposing that the GAG layer is a
secretory factor produced by the urothelium to recover itself (Parsons et al. 1975,
Muhlholland et al. 1976). Further studies showed that the secretory factor was, in fact,
the mucin glycoprotein (MUC-1) rather than a glucosaminoglycan (Buckley et al. 1996,
Higuchi et al. 2000). Later, Lavelle and colleagues demonstrated that GAG and MUC-1
have no effect on the transcellular permeability of water and urea in the urothelium
(Lavelle et al. 1997). Overall, there were controversial results and no definite evidence
that the GAG layer operates as a primary barrier between urine and plasma in the
urothelium.
On the other hand, animal models have demonstrated that umbrella cells play an
important role in the permeability of water and urea. Specifically, Lavelle and coworkers
convincingly showed that the destruction of the apical layer leads to increased
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permeability, apparently through leakage of urine solutes into the lamina propria (Lavelle
et al. 1998, Lavelle et al. 2000).
There is now increasing evidence that the urothelium has additional signal transduction
properties. This statement is based on the presence of many receptors found in recent
years in the urothelium (receptors for bradykinin, neurotrophins, purines, norepinephrine,
acetylcholine (ACh), transient receptor potential (TRP) channels and others). Activation
of these receptors in a response to chemical or mechanical stimuli leads to release of
mediators such as NO, ATP, ACh and substance P (SP) (Ferguson et al. 1997, Birder et
al. 1998, Burnstock et al. 2001a). These mediators may act directly on afferent nerves or
indirectly through suburothelial interstitial cells – myofibroblasts. Myofibroblasts are
broadly connected by gap junctions and can respond to mediators that in turn modulate
afferent nerves (Fowler et al. 2008). Therefore, it is believed that urothelial cells and
myofibroblasts can cooperate in sensory mechanisms in the urinary tract by chemical
coupling to the bordering sensory nerves.
1.3.2 Lamina propria
The lamina propria (LP) is located between the basal membrane of the urothelium and
the detrusor muscle (Fig. 1.2). It includes an extracellular matrix, interstitial cells (IC),
afferent and efferent nerve endings, and a rich vascular network (Dixon and Gosling 1983,
Paner et al. 2007, Paner et al. 2009, Aitken and Bägli 2009). Interestingly, many authors
deny the presence of muscularis mucosae in the LP of the human urinary bladder, unlike
in the intestine, so that in some articles the LP is referred to as a true “submucosa” (Dixon
and Gosling 1983, Paner et al. 2009). On the other hand, Ro and co-workers claimed that
the muscularis mucosae consist of irregularly arranged muscle bundles that form a
discontinuous layer (Ro et al. 1987).
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Figure 1.2 Anatomical components of the urinary bladder wall.
Interstitial cells (IC) of Cajal were first identified as pacemakers (driving the peristaltic
activity of smooth muscle and transmit the signals from nerves to smooth muscle) in the
gastrointestinal tract by Sanders in 1996 (Sanders 1996). In analogy, the presence of IC
was presumed in the urinary bladder (Smet et al. 1996, Davidson and McCloskey 2005).
Over the last decade, increasing evidence argues for the role of IC in the modulation of
bladder smooth muscle activity and sensory processing. To identify IC in the bladder,
different antibodies were used, such as those against vimentin, tyrosine receptor KIT, and
platelet-derived growth factor receptor alpha (PDGFRα) (Koh et al. 2012, Monaghan et
al. 2012). Unfortunately, these antibodies did not label exactly the same cellular
population. Moreover, it was observed that different subtypes of IC in the urinary bladder
could co-express two or more of these markers (Andersson et al. 2014). Up to this day,
we distinguish four different subtypes of IC in the bladder wall. IC of the lamina propria
(IC-LP) forms a cellular network interconnected by gap junctions consisting of connexin
43 (Davidson and McCloskey 2005). Detrusor-IC (IC-IM), unlike IC-LP, do not build up
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a network and are arranged on the border of smooth muscle bundles (er et al. 2013).
Interbundle IC (IC-IB) as a name tells us that they are located between detrusor bundles.
The last known subtype is perivascular IC described by Cunningham (Cunningham et al.
2011). All IC according to their morphology, regardless of their subtype, are located close
to nerves (Davidson and McCloskey 2005, Sui et al. 2002, Johnston et al. 2010).
Mukerji and coworkers reported the expression of the muscarinic M2 and M3 receptors
in IC-LP. This finding was confirmed later also by Grol et al. so that they suggested that
these cells respond to muscarinic stimuli (Mukerji et al. 2006, Grol et al. 2009). However,
Sui and coworkers reported that the suburothelial IC did not respond to the application of
the muscarinic agonist, carbachol, but are sensitive to ATP application. ATP induces
Ca2+-activated chloride currents (Sui et al. 2004, Sui et al. 2008). This could be explained
by the expression of purinergic receptors (P2X3, P2Y2, P2Y4, P2Y6) (Sui et al. 2006).
Ost reported also an expression of transient receptor potential cation channel subfamily
V member 1 (TRPV1) on IC-LP (Ost et al. 2002). Different studies have concluded that
IC-LP may be associated with many other Slosksignal systems (Nile et al. 2010,
Rahnama’ I et al. 2010, Nile and Gillespie 2012). However, the functions of bladder ICs
are not completely understood yet.
Figure 1.3 Schematic representation of suburothelial interstitial cells. Substances released
from the basolateral surface during stretches, such as adenosine triphosphate (ATP) and
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acetylcholine (ACh), activate afferents in the suburothelial layer. Interstitial cells express
purinergic P2Y receptors, muscarinic M2, and M3- receptors, or capsaicin receptors
(TRPV1) receptors, and are connected to one another by gap junctions.
1.3.3 Smooth muscle
The architecture of the bladder detrusor differs from smooth muscle layers in the ureter
or gastrointestinal tract. One particular feature is a distinctive organization in fascicles.
They settle in a random direction (Donker et al. 1982). Each muscle cell in a bundle is
connected with others and they form a functional syncytium.
Postganglionic parasympathetic nerve fibers innervate the detrusor muscle. Not each
smooth muscle cell receives direct synaptic contact. Due to the presence of gap junctions,
the excitation spreads through the smooth muscle syncytium (Gillespie et al. 2006).
Neuronally induced detrusor contraction is mainly mediated through ACh and ATP.
When muscarinic and purinergic receptors are activated by their agonists, these receptors
initiate the excitation-contraction coupling of the smooth muscle in the urinary bladder
(Andersson and Arner 2004, Nausch et al. 2010, Bayliss et al. 1999).
1.4 Peripheral neural control of the lower urinary tract
The innervation of LUT is accomplished by three sets of efferent peripheral nerves: sacral
parasympathetic (running in the pelvic nerves), thoracolumbar sympathetic (in
hypogastric nerves) and sacral somatic pathway (in pudendal nerves). Each of these
nerves contains afferent in addition to these efferent (motor) axons. The afferent axons in
the pelvic, hypogastric, pudendal and levator ani nerves convey information from the
LUT and pelvic floor to the dorsal horn in the lumbosacral spinal cord (de Groat 1986,
Yoshimura and de Groat 1997).
1.4.1 Parasympathetic pathway
The parasympathetic preganglionic neurons are located in the lateral part of the sacral
gray matter (Nadelhaft et al. 1980, Morgan et al. 1981, de Groat et al. 1993). They are
carrying information from the spinal cord to the bladder and urethra. Parasympathetic
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postganglionic neurons are effectors of excitatory transmission in the bladder (de Groat
and Booth 1993). They located in the detrusor wall as well as in the pelvic plexus (De
Groat et al. 1993, De Groat et al. 1996).  This location is crucial to know in patients with
lesion of the spina equina or the pelvic plexus because afferent and efferent neuron
interconnection is possible at the level of the intramural ganglia.
The activation of the postganglionic parasympathetic nerve leads to the release of ACh
and ATP in the bladder (Andersson 1993, Andersson and Arner 2004). However, it is
unclear whether the purinergic ligands are released together with ACh from the same
nerve fibers as a cotransmitter or from a separate fiber population. The concept of
cotransmission is now well accepted as an integral feature of neurotransmission
(Burnstock 1976, Burnstock 1990a). Unfortunately, there is little information about
cholinergic/ATP-cotransmission within the parasympathetic nervous system (Burnstock
et al. 2001b). The paucity of data addressing parasympathetic cotransmission is probably
due to the fact that it is harder to surgically or chemically denervate postganglionic
parasympathetic nerves than postganglionic sympathetic nerves (Burnstock et al. 2001b).
Several studies present indirect evidence for cholinergic/purinergic cotransmission. In the
seventies, Hoyes et al. proposed that ACh and purinergic transmitters are colocalized in
small agranular and large opaque vesicles in nerve terminals (Hoyes et al. 1975). Further,
MacKenzie and coworkers showed a significant reduction of the excitatory response of
both cholinergic and purinergic component to nerve stimulation by botulinum neurotoxin
type A in the guinea-pig bladder (MacKenzie et al. 1982). Other indirect evidence for
purinergic cotransmission was described by Parija and coworkers. Using adenosine in the
rat bladder, they achieved prejunctional inhibition of both cholinergic and purinergic
components of the nerve-mediated responses (Parija et al. 1991). It appears to be likely
from pharmacological studies that a range of nerves exists, containing diverse proportions
of ATP and ACh, from predominantly ATP in cat and guinea-pig through to roughly
50:50 in rat and dog to predominantly ACh in the human bladder (Burnstock et al. 2001a).
ACh acts upon postjunctional muscarinic M2 and M3 receptors. M2 receptors inhibit
adenylate cyclase. This causes bladder contraction due to suppression of the stimulation
of adenylate cyclase through β-adrenergic receptors (Andersson and Arner 2004).
However, investigation on knockout mice revealed that the M3 is the dominant receptor
involved in the transmission (Andersson et al. 1993, Andersson and Arner 2004, Matsui
et al. 2000, Matsui et al 2002). Activation of M3 receptors causes an increase in the
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intracellular Ca2+-concentration. There are two known mechanisms leading to this
increase in intracellular Ca2+-concentration: 1) extracellular entry through L-type voltage-
dependent calcium channel (VDCC) (Anderson and Arner 2004, Anderson and Wein
2004, Schneider et al. 2004a, b, Nausch et al. 2010), 2) release of Ca2+ from intracellular
Ca2+ stores in the sarcoplasmic reticulum (SR) (Iacovou et al. 1990, Eglen et al. 1994,
Fry et al. 2002, Braverman et al. 2006a). The activation of muscarinic M3 receptors leads
to activation of a Gq-protein α-subunit and subsequent activation of the membrane-bound
enzyme, phospholipase C (PLC). The PLC cleaves a membrane phospholipid,
phosphatidylinositol 4, 5-biphosphate (PIP2), and forms cytosolic inositol triphosphate
(IP3). IP3 binds to its receptor on the SR, thereby provoking Ca2+-release.
The role of the intracellular Ca2+-increase in the contraction of the smooth muscle is
currently under debate. Nausch et al. described that during electrical field stimulation
(EFS) – a stimulus that excites nerve endings to release transmitters – smooth muscle
contraction is reduced after application of a muscarinic inhibitor (atropine) and a VDCC
blocker (diltiazem) (Nausch et al. 2010), but not by blocking of the IP3-receptor or
inhibition of the PLC. It should be mentioned that in this study the purinergic components
were blocked through α,β-methylene ATP.
The excitation of bladder smooth muscle by ATP is mediated through P2X1 receptors.
The P2X1 receptor is known as the main subtype of P2X receptors in the rat and human
bladder (Ralevic et al. 1998, Burnstock et al. 2001b). It is disputed that purinergic
transmission has an important role in excitation of animal bladders but not in the healthy
human bladder. Bayliss et al. forwarded the theory that ACh mediates contraction of the
bladder in the normal healthy state (Bayliss et al. 1999). In patients with LUT disorders,
neurotransmission works mainly through ATP. His study of human bladders from patients
with LUT obstruction and OAB revealed that the atropine-resistant contraction was
blocked by α,β-methylene ATP, a blocker of P2X receptors. Yoshida et al. demonstrated
an increasing dependence of the purinergic signaling with the aging bladder (Yoshida et
al. 2001). Recent studies in animal models revealed that activation of both purinergic and
muscarinic receptors leads to bladder contraction (Heppner et al. 2009).
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1.4.2 Thoracolumbar sympathetic pathways
Sympathetic preganglionic pathways originate from the T11 to L2 level, pass through the
synaptic chain ganglia to the inferior mesenteric ganglia and then follow the hypogastric
nerves to the pelvic plexus. Sympathetic postganglionic nerve fibers release
norepinephrine, leading to the activation of the smooth muscle of the bladder base and
urethra as well as inhibition of the smooth muscle of the bladder body. Anderson et al.
described the prevalence of α1-adrenergic receptors in the bladder base and proximal
urethra, whereas β3-adrenergic receptors are predominantly expressed in the bladder
body (Andersson and Arner 2004).
It is assumed that ATP is contained together with noradrenaline (NA) in sympathetic
nerve terminals. The first evidence for sympathetic cotransmission involving ATP
together with NA came from Su and coworkers. They demonstrated the release of ATP
during the stimulation of periarterial sympathetic nerves and blocking of both ATP and
NA release by guanethidine (Su et al. 1971). The most extensive evidence for sympathetic
cotransmission came from the investigation on the vas deference by Westfall and
colleagues. Their study showed that ATP is both a potent contractile agent and is present
in the adrenergic storage complex in the vas deferens (Westfall et al. 1978). Further,
Theobald mentioned in 1983 that ATP is also released from the hypogastric nerve. In his
experiments, after the stimulation of the hypogastric nerve and contraction of the bladder
of the cat, he used arylazido aminopropionyl ATP (ANAPP3) to reduce the contraction,
implying that ATP was released. 6-Hydroxydopamine, which destroys noradrenergic
sympathetic nerve fibers, prevents this contractile response, indicating that ATP was
released from sympathetic nerve terminals (Theobald 1983). Due to this strong evidence
that ATP acts as a cotransmitter with noradrenaline in the sympathetic nervous system,
the concept of purinergic-noradrenergic cotransmission is now well accepted.
1.4.3 Sacral somatic pathway
The efferent pathway to the external urethral sphincter (EUS) arises from Onuf´s nucleus
at the lateral border of the ventral horn in the third and fourth sacral segment (Thor et al.
1989). The fibers travel in the pudendal nerve. As the pudendal nerve passes through
Alcock’s canal, it branches into the inferior rectal nerve (which innervates the anal
rhabdosphincter), the perineal nerve (which innervates the striated urethral sphincter, the
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bulbospongiosus muscle, the ischiocavernosus muscle, superficial perineal muscle and
labial skin), and the dorsal nerve of the clitoris or penis, respectively (de Groat and
Yoshimura 2015).
1.4.4 Afferent Pathways
Afferent axons in the pelvic, hypogastric and pudendal nerves transmit information from
the LUT to the spinal cord. The cell bodies of these neurons are located in lumbosacral
dorsal root ganglia (DRG). Afferent nerve fibers that innervate the bladder and the urethra
are divided into two major populations: myelinated (Aδ) and unmyelinated C-fibers.
Aδ-fibers are mechanoreceptors that respond to passive distension as well as the active
contraction of the bladder. They are silent when the bladder is empty, but increase firing
frequency during slow filling of the bladder, indicating that they are tension receptors
(Häbler et al. 1993, Bruns et al. 2011). Electrophysiological studies in rats have revealed
that the normal micturition reflex is managed by myelinated Aδ-fiber afferents (Mallory
et al. 1989).
In contrast to the Aδ bladder afferents, the C bladder afferents are not mechano-sensitive
(Häbler et al. 1990). These afferents are nociceptive and respond to cold or chemical
stimuli (Häbler et al. 1990). The exposure of the bladder to chemical stimuli such as high
potassium, low pH, and high osmolarity, leads C-fibers to acquire mechanoreceptive
properties. It is believed that C-fiber afferents are not essential for normal voiding (de
Groat et al. 1990). However, the bladder overactivity induced by noxious stimuli can be
reduced by the application of capsaicin, indicating that C-fiber afferents play an important
role in LUT dysfunction in pathological conditions (Cheng et al. 1995, de Groat and
Yoshimura 2009, de Groat and Yoshimura 2015).
Immunohistochemical studies demonstrated that afferent neurons contain numerous
neuropeptides, such as SP, calcitonin gene-related peptide (CGRP), pituitary adenylate
cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), and
putative excitatory amino acid transmitters (Keast and de Groat 1992, Maggi 1993, Keast
and Stephensen 2000, Brumovsky et al. 2013).
Tachykinins (SP, neurokinin A, neurokinin B) and CGRP act on neurokinin (NK) 1, NK2,
NK3 or CGRP receptors, respectively (Andersson 2002). The sensory functions of the
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tachykinins include regulation of micturition threshold, activation of cardiovascular
reflexes and perception of pain from the urinary bladder (Maggie et al. 1995, Andersson
2002). Expressions of tachykinins in the LUT have been reported in animal models of
bladder inflammation and in the clinical syndrome of interstitial cystitis and painful
bladder syndrome. It has been demonstrated that intrathecal injection of SP antagonists
reduces cyclophosphamide-induced bladder hyperreflexia (Lecci et al. 1994).
1.5 Muscarinic acetylcholine receptors in the bladder smooth
muscle
Muscarinic receptors are essential for the contraction of the detrusor smooth muscle. They
consist of five subtypes (M1-M5) encoded by five distinct genes. In the human urinary
bladder, all five subtypes of muscarinic receptors are demonstrated (Sigala et al. 2002,
Bschleipfer et al. 2007). M2 and M3 receptors are dominant in the human bladder (Sigala
et al. 2002, Yamaguchi et al. 1996). Muscarinic receptors are coupled to G-proteins. The
signal transduction of M3 and M2 receptors are different. After many years of the
research, the calcium influx via L-type VDCC and increased sensitivity of the
actinomyosin cross-bridge cycling to calcium through activation of Rho-kinase is
considered as the main pathway for the contraction of the human detrusor through the M3
receptor. This leads to the inhibition of the myosin light chain phosphatase (MLCP)
(Scheider et al. 2004a, Andersson et al. 2004a), thus, tipping the balance toward the
contraction of the smooth muscle. The M2 receptor inhibits the adenylyl cyclase activity,
accordingly reducing the efficacy of β-adrenoreceptor mediated responses (Hegde et al.
1997).
In the detrusor smooth muscle of the human bladder, 10% of the muscarinic receptors are
of the M1 subtype, 20% of the M3 subtype and 70% of the M2 subtype (Mansfield et al.
2005). The ratio between M2 and M3 can vary from 9:1 to 3:1, depending on the species
(Wang et al. 1995, Yamanishi et al. 2000). Interesting results were derived from the
cystometric examination of mutant mice. For example, prolonged voiding intervals,
larger micturition volume and larger bladder capacity than the wild-type mice were
observed in M3-knockout mice (Igawa et al. 2004). The residual volume was the same in
both groups, which indicates normal bladder emptying. Probably the lack of M3 receptors
is compensated by non-cholinergic receptors (purinergic) or by another subtype of
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muscarinic receptors. Cystometric measurements in M2-knockout mice did not show a
significant increase in the micturition frequency and volume (Igawa et al. 2004). This
result again suggests that the M2 receptor mediates contraction indirectly through
inhibiting adrenergic relaxation.
1.6 Purinergic receptors in the bladder smooth muscle
Since the participation of ATP in bladder contraction is known, many efforts were
undertaken to recognize ATP receptors involved in this activity. In 1994, Abbracchio and
Burnstock described two types of ATP receptors: ionotropic P2X receptors and
metabotropic P2Y receptors (Abbracchio and Burnstock 1994). Up to date, there are 7
known subtypes of P2X ion channel receptors and 8 subtypes of P2Y G-protein coupled
receptors (Burnstock 2007, Ralevic and Burnstock 1998).
While it is well established that ATP contracts the urinary bladder, it is assumed that ATP
can also relax the detrusor muscle (Burnstock 2014). This is most likely due to the
expression of multiple purinergic receptors in the bladder.
1.6.1 P2X receptors
It seems that the P2X1 receptor is the dominant P2X receptor subtype in the smooth
muscle cell membrane of the urinary bladder, as it has been shown in
immunohistochemical studies (Lee et al. 2000). Other immunohistochemical studies
reported that P2X1 receptors spread not only in the smooth muscle of the bladder but also
in parasympathetic nerve varicosities (Hansen et al. 1998, Dutton et al. 1999).
Other molecular genetic investigations, such as Northern blotting and in situ
hybridization, described the presence of P2X1 mRNA in the urinary bladder (Valera et
al. 1995). Further Northern blot analyses detected also an expression of the P2X4 receptor
gene in the human bladder (Dhulipala et al. 1998). However, despite the detection other
receptor subtypes in the bladder, all authors agree that the P2X1 subtype is the functional
receptor subtype mediating contraction (Burnstock et al. 1978, Valera et al. 1994, Evans
et al. 1995, Hansen et al. 1998).
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1.6.2 P2Y receptors
In contrast to P2X receptors, the function of P2Y receptors in the bladder is under debate.
It is discussed that these receptors are involved in the inhibition of bladder contraction
(Theobald and de Groat 1989). There are two theories on the mechanisms underlying the
inhibitory function of P2Y receptors: 1) direct initiation of detrusor relaxation via
postjunctional P2Y receptors on the smooth muscle, 2) prejunctional inhibition of the
release of excitatory neurotransmitters (Theobald et al. 1992).
In the early 90´s, Boland et al. and Bolega et al. reported that the stimulation of purinergic
receptors with ATP induces a biphasic force response in bladder muscle strips (Boland et
al. 1993, Bolego et al. 1995). The biphasic response was characterized by an initial fast
contraction and a slower long lasting relaxation. This effect had been described already
in the respiratory, vascular, digestive and genital tract (Brown and Burnstock 1981,
Manzini et al. 1985, Ralevic and Burnstock 1991, Boland et al. 1992). Evidence advanced
that the long-lasting relaxation is mediated through a P2Y receptor in the bladder smooth
muscle. Especially, Boland et al. in their experiment precisely examined the effect of ATP
on the smooth muscle. The aim of their experiment was to induce tachyphylaxis, which
was specific for P2X receptors, applying ATP twice. After the second stimulation, the
contractile response to ATP was decreased, this effect is called tachyphylaxis.
Interestingly, however, the relaxation caused by ATP was not decreased. These results
lead to the conclusion that the two opposing effects are mediated through two different
purinergic receptors (Boland et al. 1993).
Further studies, using molecular analysis such as RT-PCR (reverse transcription-
polymerase chain reaction), Northern blotting and in situ hybridization demonstrated the
expression of P2Y1, P2Y2 and P2Y4 receptors in the smooth muscle of the urinary
bladder (Obara et al. 1998).
The physiological function of P2Y receptors in the detrusor muscle is not completely
known. They could play an essential role in relaxing the bladder muscle during the storage
phase. On the other hand, recent data describe the presence of P2Y receptors on the
bladder neck (Tong et al. 1995). Thereby, a role in micturition through relaxing the
bladder neck needs also to be considered.
22
1.7 Neuromodulation of detrusor contraction
Nerves innervating the detrusor mostly express acetylcholinesterase and the vesicular
acetylcholine transporter (VAChT) and are considered to be parasympathetic (Ek et al.
1977, Dixon et al. 1983). Such parasympathetic postganglionic fibers release ACh,
resulting in detrusor contraction. In addition, early studies demonstrated that also ATP
plays an important role in detrusor contraction (Burnstock et al. 1978, Valera et al. 1994,
Evans et al. 1995). EFS studies have been used to investigate the neurotransmitter
released from muscle strips. These studies revealed that EFS responses are blocked by
muscarinic receptor antagonists combined with purinergic antagonists (Lawrence et al.
2010) so that both ACh and ATP seem to provide most of the excitatory input (Fig. 1.4).
Beside ACh and ATP, there are additional substances present in parasympathetic
efferents (nitric oxide synthase (NOS), vasoactive intestinal polypeptide (VIP), β- NAD,
etc.), which raise the question whether extra transmitters (other than ACh and ATP) have
a part in regulating normal micturition or in disease pathophysiology (Lundberg 1981,
Callsen-Cencic and Mense 1997, Breen et al. 2006).
Figure 1.4 The innervation of the bladder, urethra and external urethral sphincter. The
parasympathetic fiber of the pelvic nerve stimulates the bladder detrusor muscle,
mediated by muscarinic and purinergic receptors and relaxes the urethral smooth muscle,
mediated by nitric oxide. The sympathetic hypogastric nerve stimulates the urethral
smooth muscle, mediated by α1-adrenergic receptors and inhibits bladder detrusor
contraction, mediated by β3-adrenergic receptors. The somatic pudendal nerve stimulates
striated muscle of the external urethral sphincter, mediated by nicotinic receptors.
Sensory nerves are located in the whole urothelium mediated by tachykinins, CGRP or
neurokinin receptors. Plus and minus signs describes neural stimulation and inhibition,
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respectively. ACh: acetylcholine; ATP: adenosine triphosphate; NO: nitric oxide; NA:
noradrenaline; CGRP: calcitonin gene-related peptide; SP: substance P.
Additionally, it is still not clarified if ATP is released from separate nerve fibers or
together with ACh as a cotransmitter from postganglionic parasympathetic nerve fibers
in the urinary bladder. By the early seventies, evidence that nerves could in fact release
more than one substance as a neurotransmitter was accumulating (Su et al. 1971, Dowdall
et al. 1974, Lagercrantz and Stajärne 1974). Numerous techniques, such as myography,
electrophysiology and biochemical measurement of neurotransmitter release, have been
used to show that ATP has cotransmitter roles in peripheral nerves. Still, all these
techniques affect more than a single fiber population. Electrophysiological stimulation,
for example, excites all nerve fibers and, thus, has a lack of specificity for the cell type.
Pharmacological manipulation is specific for receptors, but these may be expressed by
several functionally distinct nerve fiber populations. Further, this technique has a low
temporal resolution. To overcome these problems, we used a new technique with
temporal precision and high cell specificity. This technique is called optogenetic
stimulation.
1.8 Optogenetics
In 1979, Francis Crick proposed the need for a method, which activates all neurons of one
type, leaving the other unaltered (Crick 1979). Many different manipulations were
developed to fulfill the criterion set by Crick, but only optogenetics succeeded.
“Optogenetics is the combination of genetic and optical methods to achieve gain or loss
of function of the well-defined event in the specific cells of living tissue.” (Deisseroth
2010). Initially, optogenetics was developed to enhance our knowledge of fundamental
neuroscience. To this day, optogenetics expands our knowledge beyond the nervous
system. The reason is that optogenetics promotes the control of defined events in a defined
cell type and at a defined time (Deisseroth 2011). In other words, this technique allows
turning defined groups of neurons on and off safely in freely moving animals, avoiding
the development of compensatory effects.
The basic principle of optogenetics is to express photosensitive proteins in a defined cell
group. These proteins are ion channels, so that illumination with light of certain
wavelengths allows the inflow of cations or anions in the cell and, hence, causes
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depolarization (excitation) or hyperpolarization (inhibition) of this cell. In nature, there
are several natural photosensitive proteins: bacteriorhodopsin (BR), described by
Stockenius and Oesterhelt in 1971, halorhodopsin (NpHR), described by Matsuno-Yagi
and Mukohata in 1979, and channelrhodopsin (ChR), described in 2002 by Nagel
(Oesterhelt et al. 1971, Matsuno-Yagi et al. 1997, Nagel et al. 2002).
Miesenböck reported a pioneering work of a cell-specific activation of neurons. He and
his coworkers described the interaction of invertebrate rhodopsin with other proteins
through activation of ligand-gated ion channels during the stimulation of a synthetic
photo-caged precursor (Zemelman et al. 2002). Around this time, Nagel and colleagues
showed that rhodopsins are directly light-gated ion channels (Nagel et al. 2002). In their
experiments, they expressed channelrhodopsin-1 (ChR-1), from the green algae
Chlamydomonas reinhardtii, in mammalian cells. A year later Nagel et al. described that
mammalian cells expressing channelrhodopsin-2 (ChR-2) can be depolarized by a light
stimulus (Nagel et al. 2003). In 2006, Deisseroth and his group successfully delivered the
gene expressing ChR2 to rat hippocampal neurons using a viral delivery method
(Deisseroth et al. 2006).
All opsins have structural similarities with each other. However, in their working
principle, ChRs are completely different from NpHR and BRs (Archaerhodopsin (Arch)
and ArchaerhodopsinT (ArchT)) (Fig. 1.5). ChRs are non-selective cation channels that
open when exposed to 470 nm blue light. The passive influx of Na+ and less Ca2+ ions
leads to depolarization (Nagel et al. 2003). In contrast, the stimulation of NpHR with 589
nm yellow light results in an influx of chloride ions into the cell and causes a
hyperpolarization with consecutive silencing of the targeted cell. Light of a wavelength
of 566 nm leads to the activation of Arch and ArchT and induces hyperpolarization of the
cell through efflux of H+ (Chow et al. 2010, Han et al. 2011).
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Figure 1.5 The optogenetic principle. Activating tools: ChR2 from Chlamydomonas
reinhardtii and ChR1 from Volvox carteri (VChR1); silencing tools: archaerhodopsin-3
(Arch) from Halorubrum sodomense and Halorhodopsin (NpHR) from Natronomonas
pharaonic.
In order to function, opsin requires a chromophore retinal. Trans-Retinal is an aldehyde
derivate of vitamin A that serves for absorption of a photon. During the illumination, all-
trans-retinal changes its conformation to 13-cis retinal (Nagel et al. 2003). This leads to
a channel opening or a pump activation and inhibition or activation of the neuronal
activity. Within milliseconds retinal returns to its trans-retinal state. The retinal is
sufficiently present in the mammalian tissue so that optogenetic tools could be used
without exogenous retinal supplementation. Nevertheless, invertebrate models need the
retinal supplementation in order for optogenetic tools to function.
There are two known methods of targeted delivery of the optogenetic tools. The first one
is viral gene transfer in vivo. This method has been effectively applied to mice, rats, and
non-human primates. Various viral vectors such as adeno-associated viruses (AAV),
lentiviruses and, rarely, herpes simplex virus (HSV) have been used for targeting
(Adamantidis et al. 2007; Carter et al. 2010; Covington et al. 2010). The advantages of
viral targeting are a short interval from virus production to the opsin expression and broad
applicability. However, the length of the genetic information a virus can carry is limited.
The second option of targeting is a generation of a transgenic animal. Using a strong
promoter in combination with the Cre-loxP system achieves a cell type-specific
expression. In other words, the promoter drives the expression of ChR2 or NpHR. An
advantage of this method is the possibility to express the rhodopsin in a specific cell type
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throughout the body. However, it takes more effort and time to generate a stable
transgenic line.
1.9 Channelrhodopsin
Channelrhodopsins (ChR) are the only known light-gated ion channels and are derived
from Chlamydomonas reinhardtii. These channels are seven transmembrane helix
proteins with covalently linked retinal that provide green algae with photophobic and
phototaxis responses (Nagel et al. 2003). The photoreceptor is located in the pigmented
eyespot region. After only a few years of the first introduction the transformation of algal
channelrhodopsin into neurons, it became one of the important tools in neuroscience
(Boyden et al. 2005). It also has been applied to activate cardiac myocytes, skeletal
muscle or used to control the behavior of invertebrates (Aponte et al. 2010, Pianca et al.
2017).
ChRs are inserted into the plasma membrane and mediate changes in the membrane
potential in response to blue light (Boyden et al. 2005). This membrane potential change
should be ideally instantaneous and predictable. However, properties of the plasma
membrane such as resistance and capacitance can limit the rate and level of the obtainable
depolarization. In addition, the unique properties of each ChR have a significant impact
during the experiment to control the depolarization with light. The following seven
properties of ChRs can influence the precision of managing the membrane potential
during the experiment (Lin et al. 2010).
1. Channel conductance directly decides the capability of the light-induced
depolarization. The single-channel conductance of ChR2 is less than the conductance of
a common membrane channel and is less than 1 pS (picosiemens) (Nagel et al. 2003).
2. Ion selectivity. All ChRs have broad cation conductance and are non-selective towards
H+, Na+, K+ and Ca2+ (Tsunoda and Hegemann 2009, Gunaydin et al. 2010).
3. Kinetics. Opening and closure rates of ChRs are basic factors accomplishing transient,
exact control of the membrane potential. The ideal kinetics of ChR should be as fast as it
is physically possible. However, very rapid kinetics leads to decreasing light sensitivity
(Lin et al. 2009a).
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4. Desensitization and recovery from the desensitized state. During the strong, continuous
or pulsed stimulation, the response of ChR2 extinct to 80% from a peak response (Nagel
et al. 2003). All known ChRs desensitize, and some variants do not recover
(Schoenenberger et al. 2009).
5. Light sensitivity. The ChRs have different light sensitivity. As mentioned before, each
mutation that leads to an increase in sensitivity has a negative effect on the kinetic
properties of the channel (Lin et al. 2009a).
6. Spectral response. The maximal and steady-state components of the photocurrents can
have different spectral excitation peaks. For example, using the second light pulse with a
different wavelength on ChR could speed up the recovery time after the desensitization
(Lin et al. 2009 a, b).
7. Membrane trafficking and expression. Low expression of ChRs results in low
effectiveness on membrane depolarization (Lin et al. 2009b). Overexpression of an
exogenous membrane protein can adversely affect the membrane properties and possibly
lead to cell death.
Several wild-types and engineered variations of ChR already have been reported. The
first wild-type ChR that was characterized ex vivo was named ChR1 (Nagel et al. 2002).
ChR1 has a low conductance at pH 7 and this limits its use as a scientific tool. In 2005,
Boyden et al. introduced another wild-type ChR, ChR2. This group was able to excite
neurons expressing ChR2 with light. ChR2 has a rapid on-rate and a moderate channel
closing time. The conductance of ChR2 is between 50-250 femtosiemens (fS). The main
disadvantage of ChR2 is the high level of desensitization. The recovery time after the
desensitization is estimated to be 25 s in the dark (Lin et al. 2009a).
ChR-2 with H134R mutation shows a slight decrease in desensitization, a slight increase
in light sensitivity and a slower channel closing (Lin et al. 2009a, b). These changes lead
to stagnation in the kinetics and less temporal precision of ChR2/H134R than ChR2. Each
published variation of ChR2 has its own advantages, and these benefits could be usefully
applied in experiments. For example, ChR2/C128X is useful for inducing a prolonged
depolarization when temporal precision is not critical. CheTA (E123T mutation in ChR2)
is useful for high-frequency stimulations. Chimera EF with I170V mutation is the best
ChR2 for experiments with high frequency, repetitive stimulation or continuous
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illumination (Lin et al. 2010). Despite many ChR modifications have been developed,
many properties still need to be optimized to generate better ChRs.
1.10 Aim of the study
Micturition is initiated and controlled by the autonomic nervous system. The two major
neurotransmitters leading to detrusor contraction are ACh and ATP. Currently, it is still
unclear if both neurotransmitters are co-released together from single nerve fibers or
separately from different sets of autonomic neurons which then could be differently
affected in disease but also selectively targeted in therapeutic approaches. A widely used
technique to investigate for potential co-occurrence of transmitters in neurons is multiple-
labeling immunohistochemistry that allows for precise localization even at the subcellular
level. In case of small molecular weight transmitters against which antibodies can be
hardly generated, the respective transmitter synthesizing enzyme is often taken as a useful
surrogate. This allows for reliable identification of cholinergic neurons by demonstration
of the ACh synthesizing enzyme, choline acetyltransferase (ChAT). ATP, however, is
synthesized by all cells as it generally serves as an energy source for multiple cellular
reactions. Thus, a pure demonstration of its presence within a cell does not provide clues
as to its use as a transmitter, and a functional readout is needed. Organ bath experiments
recording detrusor contraction represent such a suitable readout. To decide whether ATP
is indeed released from cholinergic nerve fibers, a method that allows for selective
stimulation of only cholinergic neurons is required. While general depolarization of all
axons within the preparation by electrical field stimulation does not fulfill the selectivity
criterion, optogenetics present as a suitable tool. Thus, we first generated mouse strains
expressing ChR2 selectively in cholinergic neurons, validated this model, and then
analyzed transmitters inducing detrusor contraction which are released from cholinergic
nerve fibers by pharmacological profiling.
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2 Materials and Methodology
2.1 Materials
2.1.1 Experimental animals
All studies involving animals described in this work were carried out conforming to the
German animal welfare act and were registered by the Regierungspräsidium Giessen
(Animal euthanasia - Tiertötung Meldung Nr: 572_M and Nr: 555_M).
Using the Cre/loxP recombinase system, B6N.129S6(B6)-Chattm2(cre)Lowl/J (006410,
Jackson Lab, Sacramento, USA) and B6;129-Gt(ROSA)26Sortm1(CAG-COP4*E123T*H134R,-
tdTomato)Gfng/J (012567, Jackson Lab, Sacramento, USA) mouse lines were crossed,
resulting in a transgenic mouse strain with channelrhodopsin-tomato protein expression
in cholinergic neurons (ChAT-ChR2-tdTomato) (Fig. 2.1). As a control group, we used
C57BL/6 strain (000664, Jackson Lab, Sacramento, USA) and ChATBAC-eGFP (007902,
Jackson Lab, Sacramento, USA) transgenic mice line with fluorescent visualization of
cholinergic nerve fibers. Colonies were maintained in the central animal facility of the
Justus-Liebig-University Giessen. For euthanasia, we applied 0.5 ml liquid 5% isoflurane
(Baxter GmbH, Unterschleissheim, Germany) to absorbent material in the open-drop
system. During the euthanasia, the mouse was separated from the absorbent material by
a physical barrier in a closed 3 l glass container. The isoflurane was scavenged through a
ventilated hood.
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Figure 2.1 Generation of a mouse strain expressing ChR2 in cholinergic neurons by cross-
breeding of B6N.129S6(B6)-Chattm2(cre)Lowl/J (express Cre recombinase under the control
of the choline acetyltransferase promoter) and B6;129-Gt(ROSA)26Sortm1(CAG-
COP4*E123T*H134R,-tdTomato)Gfng/J (express E123T*H134R gene and tdTomato fluorescence
protein). ChAT: choline acetyltransferase; Ub-Pr: ubiquitin promoter; E123T*H134,
tdTomato: gen expressing ChR-2 and tomato protein.
2.1.2 Pharmacological substances
All pharmacological substances used during the experiment are listed in Table 2.1.
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Substance Function Target Concentration Solvent Source
Muscarine
chloride
Agonist Muscarinic
receptors
10-5–10-8 M Ampuwa® Sigma
Aldrich,
Steinheim,
Germany
Atropine
sulfate
Antagonist Muscarinic
receptors
2 µM Ampuwa® Sigma
Aldrich,
Steinheim,
Germany
Mecamyl-
amine
Antagonist Nicotinic
receptors
20 µM Ampuwa® Sigma,
Missouri,
USA
Suramin
sodium salt
Non-
selective
antagonist
Purinergic
receptors
300 µM Ampuwa® Sigma
Aldrich,
Steinheim,
Germany
Pyridoxal-
phosphate-
6-
azophenyl-
2’, 4’-
disulfonic
acid
(PPADS)
tetrasodium
salt
Non-
selective
antagonist
Purinergic
receptors
100 µM Ampuwa® Sigma
Aldrich,
Steinheim,
Germany
Table 2.1 Agonist and antagonists used in organ bath experiments.
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2.1.3 Antibodies
The characteristics of primary and secondary antibodies used in immunohistochemistry
are listed in Table 2.2 and Table 2.3, respectively.
Antigen Host Dilution Source
ChAT Goat, Polyclonal 1:250 Millipore, Temecula, California
VAChT Goat, Polyclonal 1:100 Biotrend, Cologne, Germany
Tyrosine
Hydroxylase
Sheep, Polyclonal 1:800 Millipore, Temecula, California
Substance P Rat, Monoclonal 1:400 Santa-Cruz, Heidelberg, Germany
Table 2.2 Characteristics of primary antibodies. ChAT: choline acetyltransferase;
VAChT: vesicular acetylcholine transporter.
Antigen Host Conjugate Dilution Source
Rat-Ig Donkey FITC 1:400 Dianova, Hamburg
Goat-Ig Donkey CF 488A 1:2000 Dianova, Hamburg
Table 2.3 Characteristics of secondary antibodies. Ig: immunoglobulin; FITC: fluorescein
isothiocyanate.
2.1.4 Solutions and Buffers
Aqua ad injectabila (Ampuwa® (B. Braun, Melsungen, Germany)
Water to aliquot the pharmacological substances.
1% Penicillin-streptomycin in minimum essential medium (MEM)
50 U Penicillin and 500 g streptomycin in 500 ml MEM solution without glutamine and
phenol red (ThermoFischer Scientific, Dreieich, Germany).
Paraformaldehyde (PFA) 4% in 0.1 M phosphate buffer pH 7.2-7.4
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40 g Paraformaldehyde powder solved in 500 ml distilled water was heated to
approximately 70 °C in a ventilated hood. Afterward, 2 M NaOH was added dropwise
with a pipette until the solution clears. Once the paraformaldehyde was dissolved, the
solution was cooled and filtered. Lastly, we added 500 ml 0.2 M phosphate buffer and
adjusted the pH at 7.4. All reagents were obtained from Merck (Darmstadt, Germany).
Phosphate buffered saline (PBS)
NaCl 137 mM, KCl 2.7 mM, phosphate 12 mM (NaCl 8 g, KCl 0.2 g, Na2HPO4 1.42 g,
KH2PO4 0.27 g in one liter distilled water); all reagents from Sigma Aldrich (Steinheim,
Germany).
Histoblock solution
10% Horse serum (HS), 0.5% Tween 20, 0.1% bovine serum albumin (BSA) in PBS. All
reagents were obtained from Merck (Darmstadt, Germany).
Zamboni fixative
Zamboni fixative contains 800 ml distilled water, 4.3 g NaOH, 20 g PFA, 18.8 g NaH2PO4
and 150 ml saturated picric acid. All reagents were obtained from Merck (Darmstadt,
Germany).
Carbonate-buffered glycerol
Glycerol and buffer (50 ml 0.5 M sodium hydrogen carbonate solution and 0.5 M sodium
carbonate at pH 8.6; all reagents from Sigma Aldrich, Steinheim, Germany) are mixed in
a ratio of 1:1.
2.2 Methods
2.2.1 Genotyping of mice
Genotyping was performed by Dr. Amir Rafiq, Institute for Anatomy and Cell Biology,
Justus-Liebig-University Giessen. Mouse-tail deoxyribonucleic acid (DNA) for
genotyping was extracted following instructions provided with KAPA mouse genotyping
kit (VWR International GmbH, Darmstadt, Germany). 2x KAPA2G Fast Genotyping Mix
with Dye was obtained from VWR International GmbH, Darmstadt, Germany. This
master mix contains all necessary ingredients for polymerase chain reaction (PCR) such
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as DNA polymerase, buffer salt solution and deoxynucleotides (dNTPs) and gel loading
dye. ChR2-tdTomato genotyping was performed by using forward primer
“caacgtgctggttattgtgc” and reverse primer “gccgaattcgatctagcttg”. The composition of the
PCR mixture is given in Table 2.4.
Component Per 30 µl reaction Final concentration
PCR-grade water 12.37 µl N/A
2x KAPA2G Fast Genotyping Mix with
Dye
15 µl 1x
Forward and reverse primer 0.63 µl 500 nM
Template DNA 1.0 µl 10 ng/µl
Table 2.4 Components for preparing PCR mixture.
The PCR was conducted using a thermal cycler (Master Cycler®, Eppendorf, Hamburg,
Germany) using the conditions specified in Table 2.5.
Step Temperature Time duration Cycles
Initial denaturation 95 ˚C 4 min 1
Denaturation 95 ˚C 20 s
35 cyclesAnnealing 60 ˚C 20 s
Extension 72 ˚C 30 s
Final extension 72 ˚C 5 min 1
Table 2.5 Steps and temperature cycles of PCR.
The PCR products were analyzed by 2% Tris-acetate-EDTA (ethylenediaminetetra-acetic
acid) agarose gel electrophoresis.
35
2.2.2 Preparation of the tissue
2.2.2.1 Dissection of the urinary bladder
After euthanasia with an overdose of isoflurane, we settled a mouse on a supine position.
The extremities were fixed. We performed a midline transperitoneal incision that
extended from just over the pubis to well above the umbilicus. As a next step, we opened
the peritoneum in the midline, retracted the intestine and dissected the aorta abdominalis
to bleed the mouse. Then, the urinary bladder was freed from perivesical fat and removed.
After cystectomy, the urinary bladder was placed in a 10 ml centrifuge tube filled with
1% penicillin-streptomycin in a modified MEM solution without glutamine and phenol
red. The conveyance lasted approximately 10 min.
The urinary bladder was fixed with needles on the bottom of a petri dish covered with
sylgard. The bladder was divided along the longitudinal axis into two equal parts. We
trapped each part between two clamps at six and twelve o´clock position. One of the
clamps had a silk suture so that the tissue could be fixed and strained on a tensiometer
(PowerLab 8/30 ADInstruments, Bella Vista, Australia) in the organ bath.
2.2.2.2 Extraction of control tissue
To characterize the expression of the ChR2-tdTomato fusion protein in ChAT-ChR2-
tdTomato mice, control tissues with known cholinergic innervation were taken from 10
animals and processed for cryosectioning and immunohistochemistry as described above
for urinary bladders. These controls were larynx, trachea, lung, esophagus, and
duodenum.
2.2.3 Organ bath experiments
For organ bath experiments, we used a 4-chamber tissue bath system produced by Radnoti
(Radnoti LLC, Monrovia, USA). Each tissue bath contained 15 ml of buffer solution. As
a buffer solution, we used 1% penicillin-streptomycin in a modified MEM solution. The
oxygen supply was maintained via direct saturation of the buffer solution in a chamber
with a carbogen (95% oxygen and 5 % carbon dioxide). The flow pressure was
preinstalled at 1 psi, furthermore, the aeration stream was controlled individually for each
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tissue bath with a needle valve at the bottom of the chamber. This setup is schematically
shown in Figure 2.2. A stable temperature of 37°C was maintained through a Thermos
Bath Heater (Radnoti LLC, Monrovia, USA).
Figure 2.2 Schematic representation of the organ bath. 1: Force transducer; 2: Organ bath
chamber; 3: Connection to the thermal circulation pump; 4: Bottle of the gas mixture:
carbogen (95% oxygen and 5 % carbon dioxide)
The urinary bladder was placed in the bath. To measure tension, one end of the urinary
bladder was attached to a fixed hook with paddles for electrical impulse and the other end
strained to a force transducer. The force transducer converted the force generated by the
tissue, measured in grams (g), after stimulation into an electrical signal. These signals
were collected on a LabChart7.0 recorder (ADInstruments, Bella Vista, Australia) (Fig.
2.3).
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Figure 2.3 Lab Chart Data screenshot. Data received from four channels during the
stimulation of bladders from ChAT-ChR2 mice. Here, the light stimulation (8, 16 and 32
Hz) alternates with EFS (8, 16 and 32 Hz)
The stimulation of the tissue was provoked by EFS via electrodes in the organ bath, or by
direct illumination of the tissue with LED, or by adding pharmacological agents in the
buffer solution.
As a light source, we used a Prizmatix Optogenetics-LED-Blue (Givat-Shmuel, Israel).
This is a fiber-coupled LED application. The module yields high power blue light (~460
nm) that triggers the opening of the channel protein ChR2. Through the pulser module,
we generated trains of pulses for optogenetic activation directly from the computer. The
setup is shown in Figure 2.4.
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To enable the visual design of the various pulse conditions, a Graphic User Interface
(GUI) was used. Figure 2.5 demonstrates the setting of GUI for an example stimulus.
Figure 2.5 Train setting Tab, screenshot from Prizmatix Pulser Software Version 2.3.1
(Givat-Shmuel, Israel). On the upper right side of the GUI exposed the legend of user
definable parameters. The bottom plane demonstrates the waveform that was
programmed with the user settings on the left side
The urinary bladder was pre-stretched between 0.5-0.7 g for 30 min. After this calibration
period, we started the experiment.
USB PULSER
LED
ControllerTTL out
TTL in
Figure 2.4 PC control with a direct connection to LED. TTL: Transistor-transistor logic
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Two different settings were used in our experiment. In a first step, we recorded the
response curve of bladders from ChAT-ChR2tdTomato mice (n=6) to illumination (460
nm; 1 Hz; 2 Hz; 4 Hz; 8 Hz; 16 Hz; 32 Hz; pulse duration respectively: 500 ms; 250 ms;
125 ms; 62.5 ms; 31.25 ms; 15.63 ms; pulse train 25 s) and then to EFS (10 V; 150 mA;
1 Hz; 2 Hz; 4 Hz; 8 Hz; 16 Hz; 32 Hz; pulse duration: 2 ms and pulse train: 10 s).
Afterward, the contractility and viability of the urinary bladder were controlled by adding
increasing concentrations of muscarine (10-5 M) (Fig. 2.6). The same procedure was
carried out for control bladders taken from ChAT-eGFP (n=6) and C57BL/6J (n=6) mice.
1   2   4   8  16  32 Hz
HHz H
1   2   4   8  16  32 Hz
EFSLED
Time (s)
Muscarine 10-5-10-8M
Figure 2.6 Protocol for obtaining stimulus-response curves. LED is light exposure with
1-32 Hz (460 nm; 2-500 ms; 25 s). EFS is electrical field stimulation at 1-32 Hz (10 V;
150 mA; 2 ms; 10 s). Muscarine was added at an increasing concentration (10-5-10-8 M)
In a further step, we stimulated urinary bladders of Chat-ChR2-dtTomato mice with LED
(8, 16, 32 Hz) and EFS (8, 16, 32 Hz). Then, we added 2 µM of the muscarinic inhibitor
atropine sulfate and repeated the LED and EFS excitation (Fig. 2.7). Afterward, the EFS
and LED stimulation of detrusor were performed in the presence and absence of the
muscarinic inhibitor atropine (2 µM) and nicotinic inhibitor mecamylamine (20 µM). The
same protocol was run using purinergic inhibitors, i.e. 300 µM suramin sodium salt and
100 µM PPADS tetrasodium salt. Lastly, we used all three antagonists to inhibit the
response of urinary bladders (atropine sulfate 2 µM, suramin sodium salt 300 µM, PPADS
100 µM). In all protocols, muscarine 10-5 M was added at the end of the experiment to
validate the effectiveness of atropine addition in protocol №1, №2 and №4 and viability
of the preparation in protocol №3. For protocol №1, №3, №4 were six organ bath
experiments conducted. Five organ bath experiments were carried out using protocol №2.
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Figure 2.7 Protocol for determining the signal pathway of the light-induced contraction
of the detrusor muscle in ChAT-ChR2 mice. a: Protocol №1, muscarinic inhibitor
(atropine sulfate 2 µM); b: Protocol №2, muscarinic and nicotinic inhibitors (atropine
sulfate 2 µM and mecamylamine 20 µM); c: Protocol №3, purinergic inhibitors (suramin
sodium salt 300 µM and PPADS tetrasodium salt 100 µM); d: Protocol №4 cocktail of
muscarinic and purinergic antagonists (atropine sulfate 2 µM, suramin sodium salt 300
µM, PPADS tetrasodium salt 100 µM)
2.2.4 Immunohistochemistry
After the experiments in an organ bath, the bladders were shortly rinsed in distilled water
and then fixed by immersion for at least four hours in Zamboni fixative. Afterward, the
fixed tissue was rinsed several times in PBS for 15 min until the yellow color was
completely washed out. For cryoprotection, it was rinsed in PBS with 18% sucrose until
it sank. The tissue was then embedded with Tissue Tek® O.C.T™ (Sakura, Zoeterwoude,
Netherland) in cryomolds. Lastly, the tissue was rapidly frozen in melting isopentane
(Fluka, Sigma, Taufkirchen, Germany) cooled with liquid nitrogen, and kept at -80°C
until further processing.
Frozen sections from urinary bladder and control tissues were prepared with a cryostat
(Leica CM 1900, Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany) at -20°C. For
this purpose, we fastened the bladder tissue using Tissue-Tek on a sample holder inside
the cryostat. We cut the sample to 10 µm sections. The sections were mounted on
microscope slides (SuperFrost Plus, Menze-Glaeser, Braunschweig, Germany) and air-
dried. The sections were then covered with 100 µl Histoblock solution for one hour and
washed in PBS for 20 min. During incubation, the slides were stored in moist chambers
to prevent evaporation of the applied solution. This step was followed by the application
of primary antibody overnight (Tab. 2.2). After washing the slides in PBS solution, they
were coated with a secondary antibody for one hour (Tab. 2.3). The samples were washed
20 min in PBS solution, fixed 10 min in 4 % PFA, washed again in PBS, and coverslipped
with carbonate-buffered glycerol.
Slides were evaluated with an epifluorescence microscope (Axioplan 2, Carl Zeiss, Jena,
Germany). Fluorescent dyes (tdTomato, fluorescein isothiocyanate (FITC), CF488A and
Alexa Fluor® 488) and appropriate excitation and barrier filters are given in Table 2.6.
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Fluorescence dye Color Excitation filter (nm) Barrier filter (nm)
tdTomato red-orange 530-560 572-647
FITC Green 460-500 512-542
CF488A Green 460-500 512-542
Alexa Fluor® 488 cyan-green 460-500 512-542
Table 2.6 Fluorophores and filter combinations used in fluorescence microscopy.
The documentation was performed using the AxioCam HR camera (Carl Zeiss, Jena,
Germany) and the Axiovision 4.7.1 software (Carl Zeiss, Jena, Germany).
2.2.5 Statistical analysis
Statistics were calculated using IBM SPSS Statistics (Armonk, USA) version 23 for
Windows 10. The values in tables and graphs are expressed as mean ± SE.  Data were
checked for normality of distribution using the Shapiro-Wilk normality test. The data
were normally distributed. Comparison of delta values before and after application of
antagonist for the same stimuli within one ChR2 mice was performed using paired T-
Test. Additionally, we used one-way ANOVA analysis for calculating the frequency
dependency of detrusor contraction to EFS and LED-stimuli after application of
muscarinic and nicotinic inhibitor cocktail. P values less than 0.05 were regarded as
statistically significant. All graphs were created using the Microsoft Excel (Redmond,
USA) software.
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3 Results
3.1 Cellular expression of ChAT-ChR2-tdTomato
3.1.1 Native tdTomato-fluorescence in reference organs with cholinergic
innervation
From the respiratory tract, a section of larynx, trachea, and lung were evaluated by
fluorescence microscopy. Native tdTomato-fluorescence was seen without further tissue
treatment in large axons, probably those of α-motoneurons, in the superior and recurrent
laryngeal nerves. The same axons were immunoreactive for ChAT as demonstrated with
a primary ChAT antibody visualized with a FITC-conjugated secondary antibody (Fig.
3.1). Consistent with ChR2 being a membrane protein and ChAT being a cytoplasmatic
protein, the red fluorescence indicating the localization of the ChR2-tdTomato fusion
protein presented as a ring around the green fluorescence representing ChAT-
immunoreactivity (Fig. 3.1). Neurons of small parasympathetic ganglia located in the
vicinity of the larynx and at the lung hilus also displayed membrane-bound tdTomato-
fluorescence and homogeneous ChAT-immunoreactivity (Figs. 3.2 and 3.3). Through the
entire length of the airways, their smooth muscle was densely innervated by nerve fibers
with tdTomato-fluorescence whose ChAT-immunoreactivity was generally weak (Fig.
3.3). Colocalization with immunoreactivities for TH (noradrenaline synthesizing
enzyme) and SP (neuropeptide) was not observed. Very rarely, tdTomato-fluorescence
was observed in single skeletal muscle fibers of laryngeal muscles (Fig. 3.4) and in
patches of epithelial cells in the alveolar region (Fig. 3.5).
From the gastrointestinal tract, sections of esophagus and duodenum were evaluated.
Native tdTomato-fluorescence was seen in cell bodies of myenteric ganglia, numerous
nerve fibers innervating the duodenal smooth muscle layer and terminals and, to a lesser
extent, in the duodenal mucosa (Fig. 3.6). At the level of neuronal cell bodies,
colocalization with ChAT-immunoreactivity was seen. At the level of muscular nerve
terminals, there was also colocalization of tdTomato-fluorescence and ChAT-
immunoreactivity, although the signals did not match 1:1 throughout (Fig. 3.7). It could
not be resolved at the fluorescence microscope level whether this partial mismatch
reflected labeling of different nerve fibers or occurred due to the differential subcellular
localization – membrane versus axoplasm – of the underlying proteins. In the epithelial
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layer, solitary triangular-shaped ChAT-immunoreactive cells, most probably cholinergic
tuft (=brush) cells (Schütz et al. 2015), were observed. These cells did not exhibit native
tdTomato-fluorescence (Fig. 3.7). In myenteric ganglia and in nerve fibers innervating
the muscle layer, frequent colocalization of tdTomato-fluorescence with SP was visible
(Fig. 3.8).
Figure 3.1 Native tdTomato-fluorescence (red) and ChAT-immunolabeling (green),
recurrent laryngeal nerve. Red fluorescence indicates the localization of ChR2-tdTomato
fusion protein. It is found in the membrane (arrowheads) of large diameter cholinergic
axons with ChAT-immunoreactivity in the axoplasm (arrows). The boxed area is shown
at higher magnification in the inset. Bar = 20 µm
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Figure 3.2 Larynx; red fluorescence indicates the localization of ChR2-tdTomato fusion
protein, overall tissue morphology is demonstrated by green background fluorescence
without antibody staining. Two neuronal cell bodies of a local parasympathetic ganglion
display membrane-bound native tdTomato-fluorescence (arrows). The arrowhead points
to positive large diameter fibers in a recurrent laryngeal nerve branch. * = small artery
with autofluorescent internal and external elastic membrane. Bar = 20 µm
Figure 3.3 Lung hilus; native tdTomato-fluorescence (red) and ChAT-immunolabeling
(green). Neuronal cell bodies of a local parasympathetic ganglion display membrane-
bound native tdTomato-fluorescence (arrows) around ChAT-immunoreactive (green)
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cytoplasm. The bronchial smooth muscle is densely innervated by tdTomato+/ChAT+
nerve fibers (arrowheads). Bar = 20 µm
Figure 3.4 External laryngeal muscle; red fluorescence indicates the localization of ChR2-
tdTomato fusion protein, overall tissue morphology is demonstrated by green background
fluorescence. This section was processed for ChAT-immunolabeling, but ChAT-
immunoreactive structures are not seen in the field of view. Two skeletal muscle fibers
(arrows) strongly express native tdTomato-fluorescence without concomitant ChAT-
immunoreactivity. Bar = 50 µm
Figure 3.5 Lung; native tdTomato-fluorescence (red) and ChAT-immunolabeling (green).
A group of epithelial cells in the wall of an alveolar duct (arrows) displays native
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tdTomato-fluorescence without concomitant ChAT-immunoreactivity. Arrowheads point
to the cholinergic innervation of bronchiolar smooth muscle. Bar = 50 µm
Figure 3.6 Duodenum; strong native tdTomato-fluorescence (red) in myenteric ganglia
(double-headed arrowheads), numerous nerve fibers in the muscle layer (arrowheads) and
fewer nerve fibers in the mucosa (arrows). Bar = 50 µm
Figure 3.7 Duodenum; native tdTomato-fluorescence (red) and ChAT-immunolabeling
(green) are colocalized in myenteric neurons (arrowheads) and nerve fibers (arrows),
although the red fluorescence channel reveals more fibers than depicted by ChAT-
immunofluorescence. Double-headed arrowhead depicts ChAT-positive epithelial cells
that do not display tdTomato-fluorescence. Bar = 20 µm
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Figure 3.8 Duodenum; native tdTomato-fluorescence (red) and SP-immunolabeling
(green) are colocalized in myenteric neurons (arrowheads) and nerve fibers (arrows). Bar
= 20 µm
3.1.2 Urinary bladder
Neurons of intrinsic ganglia in the bladder wall and associated nerve fiber bundles
displayed intense ChR2-tdTomato-fluorescence (Fig. 3.9a). A very dense innervation by
nerve fibers with native tdTomato-fluorescence was observed in the detrusor muscle (Fig.
3.9b). Such nerve fibers also contained immunoreactivities for ChAT (Fig. 3.10) and
VAChT (Fig. 3.11), but neither for TH (Fig. 3.12) nor for SP (Fig. 3.13). In some but not
all bladders investigated (4 out of 12), single or small groups of detrusor smooth muscle
cells also exhibited tdTomato-fluorescence (Fig. 3.14).
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Figure 3.9 Urinary bladder; strong native tdTomato-fluorescence (red) a) in nerve trunks
(arrowheads) and neurons in intrinsic ganglia (arrows), and b) in nerve fiber bundles
(arrowheads) and ramifications (arrows) in the detrusor muscle. Bar = 50 µm
Figure 3.10 Urinary bladder, detrusor muscle; native tdTomato-fluorescence (red) and
ChAT-immunolabeling (green) are colocalized in nerve fibers (arrowheads). Bar = 20 µm
ChR2-tdTom ChAT merge
20 µm
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Figure 3.11 Urinary bladder, detrusor muscle; native tdTomato-fluorescence (red) and
VAChT-immunolabeling (green) are colocalized in nerve fibers (arrowheads). Bar = 20 µm
Figure 3.12 Urinary bladder, detrusor muscle; native tdTomato-fluorescence (red,
arrowheads) and TH-immunolabeling (green, arrows) occur in separate populations of nerve
fibers. Bar = 20 µm
ChR2-tdTom VAChT merge
20 µm
ChR2-tdTom
20 µm
mergeTH
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Figure 3.14 Urinary bladder; native tdTomato-fluorescence (red) is expressed by some
smooth muscle fibers (arrowheads) of the detrusor muscle in this specimen. Bar = 50 µm
Figure 3.13 Urinary bladder, detrusor muscle; native tdTomato-fluorescence (red,
arrowheads) and SP-immunolabeling (green, arrows) occur in separate populations of nerve
fibers. Bar = 20 µm
20 µm
mergeChR2-tdTom SP
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3.2 Organ bath experiments
3.2.1 Illumination of the detrusor muscle leads to a contraction in ChAT-
ChR2-tdTomato, but not in ChAT-GFP mice
Urinary bladder strips from ChAT-ChR2-tdTomato and ChAT-GFP mice were subjected
to LED and EFS stimulation and force was recorded in organ baths. EFS (8-32 Hz)
induced frequency dependent detrusor contraction in both mouse strains with no
significant differences between strains (Figs. 3.15 and 3.16, Tab. 3.3). LED, however,
evoked detrusor contraction only in ChAT-ChR2-tdTomato mice but not in ChAT-GFP
mice (Figs. 3.15 and 3.16). Constrictor responses were further characterized in ChR2-
tdTomato mice. A graded increase in force development was seen in correlation with EFS
frequency over a range of 1 to 32 Hz. At 32 Hz, contraction force almost reached that
evoked by muscarine (10-5 M) (Fig. 3.17, Tab. 3.1). Such frequency dependence was not
observed in LED stimulation with an increase of approximately 1 g in the range of 1 to
32 Hz (Fig. 3.18, Tab. 3.2). This increase was comparable to that evoked by EFS at 16
Hz, 2 ms, 10 V. It has to be noted, however, that pulse duration was kept constant in EFS
(2 ms) whereas it was adapted to equal on-off durations in this protocol of LED
stimulation (i.e. 500 ms at 1 Hz, 250 ms at 2 Hz, and so forth).
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Figure 3.15 LED-, EFS-, and muscarine-induced contraction of the urinary bladder of
ChAT-ChR2-td Tomato mice (n=21) in organ bath experiments. The responses of the
urinary bladder to LED (8, 16, 32 Hz), EFS (8, 16, 32 Hz) and muscarine 10-5 M are
shown in force (g). Mean ± S.E.M. Significant (p≤0.05, paired t-test) increases in tension,
compared to baseline, are indicated by asterisks.
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Figure 3.16 LED-, EFS-, and muscarine-induced contraction of the urinary bladder of
ChAT-GFP mice (n=15) in organ bath experiments. The responses of the urinary bladder
to LED (8, 16, 32 Hz), EFS (8, 16, 32 Hz) and muscarine 10-5 M are shown in force (g).
Mean ± S.E.M. Significant (p≤0.05, paired t-test) increases in tension, compared to
baseline, are indicated by asterisks.
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Figure 3.17 EFS-induced contraction of the urinary bladder of ChAT-ChR2 mice in an
organ bath (n=5). Control of the viability of the tissue with muscarine 10-5M. EFS stimuli:
1-32 Hz (10 V; 2 ms; 10 s). The response of the urinary bladder to stimuli is shown in
force (g). Mean ± S.E.M. Significant (p≤0.05, paired t-test) increases in tension provoked
by raising the frequency of the stimuli, compared to each other, are indicated by asterisks
Frequency 1 Hz 2 Hz 4 Hz 8 Hz 16 Hz 32 Hz
Increase in
tension [g]
0.13±0.04 0.26±0.06 0.46±0.12 1.42±0.56 1.49±0.54 2.27±0.40
Table 3.1 EFS-induced contraction of the urinary bladder of ChAT-ChR2 mice in an
organ bath (n=5).  Mean ± S.E.M. EFS stimuli: 1-32 Hz (10 V; 2 ms; 10 s).
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Figure 3.18 LED-induced contraction of the urinary bladder of ChAT-ChR2 mice in an
organ bath (n=5). Control of the viability of the tissue with muscarine at 10-5 M. LED
stimuli: 1-32 Hz (460 nm; 2-500 ms; 25 s). The response of the urinary bladder to stimuli
is shown in force (g). Mean ± S.E.M. Significant (p≤0.05) is indicated by an asterisk, n.s-
no significance (paired t-test) observed by comparing the tension provoked by raising the
frequency of stimuli, among each other
Frequency 1 Hz 2 Hz 4 Hz 8 Hz 16 Hz 32 Hz
Increase in
tension [g]
1.09±0.60 1.09±0.62 1.03±0.51 1.28±0.61 1.11±0.60 1.03±0.61
Table 3.2 LED-induced contraction of the urinary bladder of ChAT-ChR2 mice in an
organ bath (n=5). Mean ± S.E.M. LED stimuli: 1-32 Hz (460 nm; 2-500 ms; 25 s).
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Frequency
[Hz]
Mouse strain N
Increase in tension
[g] p-value
Mean±S.E.M
8 ChAT-GFP 15 0.39±0.08 0.07
ChAT-ChR2 21 0.55±0.04
16 ChAT-GFP 15 0.80±0.11 0.11
ChAT-ChR2 21 1.02±0.08
32 ChAT-GFP 15 1.82±0.21 0.06
ChAT-ChR2 21 2.45±0.22
Table 3.3 EFS-induced increase in detrusor tension in ChAT-GFP and ChAT-ChR2
mouse strains. The response of the urinary bladder to stimuli is shown in force (g). Mean
± S.E.M. Significant (p≤0.05, independent t-test) increases in tension, among ChAT-
ChR2 and ChAT-GFP mice. There is no significant difference between mouse strains.
3.2.2 The muscarinic inhibitor atropine partly reduces the detrusor
contraction evoked by EFS and LED stimulation of cholinergic
nerve fibers
Cholinergic detrusor contraction is entirely mediated by muscarinic receptors and can be
fully antagonized by atropine (Andersson 1993, Andersson and Wein 2004). To estimate
the cholinergic component, EFS- and LED-induced detrusor contraction was evoked first
in the absence and then in the presence of atropine at 2 µM. The response to LED
stimulation was reduced by 35-37% at all frequencies, while the response to EFS was
frequency dependently reduced by 5 (at 8 Hz) to 21% (at 32 Hz) (Fig. 3.19, Tab. 3.4).
Repetitive EFS and LED stimulation in the absence of atropine, however, did not show
decreased responses (Fig. 3.20, Tab. 3.5).
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Figure 3.19 LED- and EFS-induced contraction of the urinary bladder of ChAT-ChR2
mice in organ bath in the presence and absence of the muscarinic inhibitor atropine (n=7).
Efficacy of atropine treatment is demonstrated by loss of response to the muscarine.
Significant (p≤0.05, paired t-test) differences in tension, compared to the same stimulus
before atropine administration, are indicated by asterisks
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Figure 3.20 LED- and EFS-induced contraction of the urinary bladder of ChAT-ChR2
mice in an organ bath, repetitive stimulation without treatment of the tissue between the
two series of stimulation (n=4). There were no significant differences in tension,
compared to the same stimulus in the first series (p>0.05, paired t-test)
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Stimuli
Increase in tension
before atropine
treatment ∆ Force
[g]
Increase in
tension after
atropine treatment
∆ Force [g]
Diminution of increase
in response to atropine
treatment (∆∆ Force)
p-
value
±SEM ±SEM ±SEM
[g]
±SEM
[%]
LED 8 Hz 0.77±0.17 0.50±0.14 0.27±0.03 35.3±3.9 0.038
LED 16 Hz 0.98±0.28 0.63±0.15 0.35±0.13 36.1±13.3 0.049
LED 32 Hz 0.59±0.18 0.37±0.11 0.22±0.07 37.5±11.9 0.105
EFS 8 Hz 0.51±0.09 0.48±0.09 0.03±0.00 5.1±0.0 0.240
EFS 16 Hz 0.93±0.16 0.81±0.15 0.12±0.01 13.0±1.1 0.031
EFS 32 Hz 2.10±0.40 1.65±0.34 0.45±0.06 21.2±2.9 0.042
Table 3.4 Comparison of LED- and EFS-induced increases in detrusor tension in ChAT-
ChR2 mice before and after atropine (2 µM) administration. P-values calculated by paired
t-test (n=7).
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Stimuli
Increase in tension
by first stimuli
∆ Force [g]
Increase in
tension by second
stimuli
∆ Force [g]
Difference in the
response to the repetitive
stimuli (∆∆ Force)
p-
value
±SEM ±SEM ±SEM
[g]
±SEM
[%]
LED 8 Hz 0.11±0.03 0.12±0.02 -0.01±0.01 -9.1±9.1 0.622
LED 16 Hz 0.21±0.03 0.20±0.01 0.01±0.02 4.8±9.5 0.867
LED 32 Hz 0.17±0.03 0.19±0.03 -0.02±0.00 -11.8±0.0 0.616
EFS 8 Hz 0.80±0.24 0.44±0.15 0.36±0.09 45.0±11.3 0.325
EFS 16 Hz 0.93±0.19 1.08±0.20 -0.15±0.01 -16.2±1.1 0.074
EFS 32 Hz 2.33±0.78 2.79±0.56 -0.46±0.22 -19.7±9.4 0.155
Table 3.5 Comparison of LED- and EFS-induced changes in detrusor tension in ChAT-
ChR2 mice by repetitive stimuli. P-values calculated by paired t-test (n=4).
3.2.3 Combined muscarinic and nicotinic inhibition only partly reduces
the detrusor contraction evoked by EFS and LED stimulation of
cholinergic nerve fibers
To assess a potential nicotinic component in the detrusor contraction upon stimulation of
cholinergic nerve fibers, EFS- and LED-induced detrusor contraction was evoked first in
the absence and then in presence of a blocker cocktail consisting of the muscarinic
inhibitor atropine (2 µM) and the nicotinic inhibitor mecamylamine (20 µM). The
response to LED stimulation was reduced by 8-18% at all frequencies, while the response
to EFS was reduced between 24% at 8 Hz and 38% at 32 Hz (Fig. 3.21, Tab. 3.6). Despite
this variation, there was no significant frequency dependency (ANOVA).
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Figure 3.21 LED- and EFS-induced contraction of the urinary bladder of ChAT-ChR2
mice in organ bath in the presence and absence of a blocker cocktail consisting of the
muscarinic inhibitor atropine (2 µM) and the nicotinic inhibitor mecamylamine (20 µM)
(n=5). Efficacy of atropine treatment is demonstrated by loss of response to muscarine.
Significant (p≤0.05, paired t-test) differences in tension, compared to the same stimulus
before blocker administration, are indicated by asterisks
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Stimuli
Increase in tension
before a blocker
cocktail (atropine
and
mecamylamine)
∆ Force [g]
Increase in tension
after a blocker
cocktail (atropine
and
mecamylamine)
∆ Force [g]
Diminution of
increase in response to
a blocker cocktail
(atropine and
mecamylamine)
(∆∆ Force)
p-
value
±SEM ±SEM ±SEM
[g]
±SEM
[%]
LED 8 Hz 0.88±0.50 0.72±0.50 0.16±0.00 18.2±0.0 0.010
LED 16 Hz 0.87±0.51 0.77±0.47 0.10±0.04 11.5±4.6 0.169
LED 32 Hz 0.72±0.40 0.66±0.44 0.06±0.04 8.33±5.6 0.270
EFS 8 Hz 0.54±0.02 0.41±0.03 0.13±0.01 24.1±1.9 0.033
EFS 16 Hz 0.97±0.08 0.63±0.04 0.34±0.04 35.1±4.1 0.042
EFS 32 Hz 2.07±0.23 1.28±0.04 0.79±0.19 38.2±9.2 0.034
Table 3.6 Comparison of LED- and EFS-induced increases in detrusor tension in ChAT-
ChR2 mice before and after administration of a blocker cocktail consisting of the
muscarinic inhibitor atropine (2 µM) and the nicotinic inhibitor mecamylamine (20 µM).
P-values calculated by paired t-test (n=5).
3.2.4 The purinergic inhibitors (PPADS and suramin) crucially reduce the
detrusor contraction evoked by light-induced selective stimulation
of cholinergic nerve fibers
Besides ACh, ATP plays also an important transmitter role in neutrally evoked detrusor
contraction (Burnstock et al. 1978, Levin et al. 1990, Masuda et al. 1995). To assess a
potential purinergic component in the detrusor contraction upon stimulation of
cholinergic nerve fibers, EFS- and LED-induced detrusor contraction was evoked first in
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the absence and then in presence of a blocker cocktail consisting of the P2 receptors
PPADS (100 µM) and suramin (300 µM) (Fig. 3.22).
Responses to LED stimulation and EFS were significantly reduced by this blocker
cocktail, but a residual contractile response remained. Contractions evoked by LED
stimulation were reduced by 60-75 %, whereas those evoked by EFS were diminished by
only 25-30% (Tab. 3.7).  These differences between stimulation protocols were
statistically significant (p≤0.05; paired t-test).
Figure 3.22 LED- and EFS-induced contraction of the urinary bladder of ChAT-ChR2
mice in organ bath in the presence and absence of a purinergic blocker cocktail consisting
of PPADS (100 µM) and suramin (300 µM) (n=6). Control of the viability of the tissue
with muscarine at 10-5 M. Significant (p≤0.05, paired t-test) differences in tension,
compared to the same stimulus before blocker administration, are indicated by asterisks
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Stimuli
Increase in tension
before suramin and
PPADS treatment
∆ Force (g)
Increase in
tension after
suramin and
PPADS treatment
∆ Force (g)
Diminution of increase
in response to suramin
and PPADS treatment
(∆∆ Force)
p-
value
±SEM ±SEM ±SEM
[g]
±SEM
[%]
LED 8 Hz 0.79±0.16 0.30±0.10 0.49±0.06 61.9±7.6 0.027
LED 16 Hz 0.94±0.24 0.25±0.07 0.69±0.17 73.9±18.1 0.036
LED 32 Hz 0.60±0.17 0.22±0.05 0.38±0.12 62.4±20.0 0.084
EFS 8 Hz 0.61±0.04 0.42±0.08 0.19±0.04 30.7±6.6 0.019
EFS 16 Hz 1.15±0.10 0.86±0.18 0.29±0.08 25.0±7.0 0.036
EFS 32 Hz 2.87±0.40 1.97±0.42 0.90±0.02 31.6±0.7 0.001
Table 3.7 Comparison of LED- and EFS-induced increases in detrusor tension in ChAT-
ChR2 mice before and after PPADS (100 µM) and suramin (300 µM) administration. P-
values calculated by paired t-test (n=6).
3.2.5 Residual detrusor contraction after using all three inhibitors
(atropine, PPADS, suramin)
To further investigate if additional receptors or neurotransmitters participate in the
detrusor contraction during the stimulation of cholinergic nerve fibers, we blocked
purinergic P2X receptors through PPADS (100 µM) and suramin (300 µM), and
muscarinic receptors through atropine (2 µM).
The contractile responses to LED stimulation and EFS were vastly reduced (about 80%)
by a combination of these three inhibitors. Still, there was a residual contraction of about
20% evoked by both LED stimulation and EFS (Fig. 3.23; Table 3.8).
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Figure 3.23 LED- and EFS-induced contraction of the urinary bladder of ChAT-ChR2
mice in organ bath in the presence and absence of a cholinergic and purinergic blocker
cocktail consisting of atropine (2 µM), PPADS (100 µM) and suramin (300 µM) (n=7).
Efficacy of atropine treatment is demonstrated by loss of response to the muscarine.
Significant (p≤0.05, paired t-test) differences in tension, compared to the same stimulus
before blocker administration, are indicated by asterisks
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Stimuli
Increase in tension
before atropine,
suramin, and
PPADS treatment
∆ Force [g]
Increase in tension
after atropine,
suramin, and
PPADS treatment
∆ Force [g]
Diminution of increase
in response to atropine,
suramin, and PPADS
treatment
(∆∆ Force)
p-
value
±SEM ±SEM ±SEM
[g]
±SEM
[%]
LED 8 Hz 0.61±0.16 0.12±0.05 0.49±0.11 80.2±18.0 0.012
LED 16 Hz 0.81±0.25 0.13±0.05 0.68±0.20 83.5±24.7 0.033
LED 32 Hz 0.61±0.30 0.13±0.06 0.48±0.24 79.2±9.8 0.016
EFS 8 Hz 0.57±0.05 0.17±0.02 0.40±0.03 71.0±5.3 0.001
EFS 16 Hz 1.08±0.14 0.20±0.04 0.88±0.10 81.2±9.3 0.001
EFS 32 Hz 2.60±0.38 0.31±0.06 1.86±0.32 88.1±12.3 0.001
Table 3.8 Comparison of LED- and EFS-induced increases in detrusor tension in ChAT-
ChR2 mice before and after administration of atropine (2 µM), PPADS (100 µM) and
suramin (300 µM). P-values calculated by paired t-test (n=7).
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4 Discussion
4.1 Validation of the optogenetic mouse model
The present study is based upon a mouse model with a cell-type specific expression of
ChR2, a light-sensitive cation channel that is not encoded in the mammalian genome.
Hence, cell type-specific gene transfer is required to obtain such a model. In the CNS,
viral gene transfer is often used for this purpose (Carter et al. 2010, Adamantidis et al.
2007, Covington et al. 2010). This method is quick, broadly applicable and restricted to
the area of viral injection. While this spatial limitation to the area of injection may be of
advantage in several experimental settings, it prevented the use of this viral transfer in the
present context. Cholinergic neurons innervating the urinary bladder, the target in this
study, are dispersed in small ganglia in the pelvic region that are highly inaccessible and
cannot be readily identified for injection in vivo. Hence, a genetic approach utilizing the
Cre-loxP system was used. This system was originally introduced by the group of
Rajewsky (Gu et al. 1993). It requires two independently generated genetically modified
mouse strains. One of them expresses Cre (Causes recombination), a 38-kDa integrase
physiologically encoded by bacteriophage P1, driven by a specific promotor. For the
present study, a mouse line was chosen that expresses Cre under the control of the ChAT
promotor, which shall be specific for cholinergic cells. Cre mediates site-specific
recombination between specific sequences that are referred to as loxP (locus of crossover
(x) in P1 bacteriophage) sites (Sharma and Zhu 2014). If Cre is expressed in a cell that
carries two loxP sites not too far from each other in its genome, the DNA will be cut at
these sites, the sequence between the loxP sites removed, and the DNA ligated again.
Thus, the region flanked by the loxP sites will be removed from the genome. This can be
used to delete a functional gene to generate a knockout mouse, but there are also
approaches to activate a certain gene through this technique. This can be achieved by
introducing a gene driven by a strong constitutive promotor but placing a STOP in front
of the coding sequence to prevent expression. If this STOP is flanked by the loxP sites,
Cre expression will result in loss of the STOP signal and, hence, activate expression of
the previously silent gene. Here, a mouse line was chosen that carries such a construct
with a “floxed” STOP in front of the ChR2-tdTomato fusion protein. Both mouse strains,
the ChAT-Cre driver line, and the “floxed” ChR2-tdTomato line are commercially
available and were obtained from the Jackson Laboratories, Sacramento. When these
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lines are cross-bred, Cre shall be specifically expressed only in cholinergic cells, and this
shall lead to ChR2-tdTomato expression exclusively in these cells.
Unfortunately, however, this is not always the case practically. First, Cre expression can
occur spontaneously in cells even when the “specific” promotor is not activated. This is
called “leaky Cre-expression”. One of the possible reasons is a transient expression of the
driver gene in early embryogenesis, but there are also other options (Sharma and Zhu
2014). This may lead to Cre-mediated STOP removal and, hence, ChR2-tdTomato
expression in cells that are not cholinergic at the time of the investigation, i.e. false
positive expression. Second, even if expressed in the correct target cell, Cre might not
efficiently cut the DNA at the loxP site (Sharma and Zhu 2014), leading to “false
negative” cells. This efficacy can vary from cell type to cell type (Sharma and Zhu 2014).
Thus, it is common that, in mouse lines based upon this technology, there is both some
ectopic expression (false positive) and not a fully complete expression in the cell type of
interest (false negative). This technical limitation has to be taken into account, and the
mouse model has to be carefully analyzed for ectopic and incomplete expression.
Therefore, expression of the ChR2-tdTomato was controlled in the urinary bladder and
other peripheral organs with known cholinergic innervation by fluorescence microscopy,
and parallel immunofluorescence with a green fluorophore was used to identify cell types
and nerve fiber populations that express (or not express) ChR2-tdTomato. Expression
outside nerve fibers (“ectopic”) which may reflect false positive expression was very
limited. It was observed only in a very small number of skeletal muscle fibers and, to an
interindividual variable degree, in some smooth muscle cells including those of the
detrusor muscle. It has to be noted that ACh synthesis is indeed not limited to neurons.
Rather, there is a widespread non-neuronal cholinergic system comprising, but not limited
to, several epithelial and immune cells (Wessler and Kirkpatrick 2008, Kummer and
Krasteva-Christ 2014, Fujii et al. 2017). Indeed, skeletal muscle fibers have been reported
to produce ACh, but in this case, it has been ascribed to the enzyme carnitine
acetyltransferase rather than to ChAT (Tucek 1982). Thus, the very infrequent ChR2-
tdTomato expression in skeletal muscle fibers may indeed represent “leaky Cre-
expression” independent from the ChAT promotor. As the urinary bladder does not
contain skeletal muscle fibers, this minor ectopic expression was irrelevant for our
functional studies. As for smooth muscle cells, indication for ChAT-expression has been
provided, mainly based upon ChAT-immunolabeling (Wessler and Kirkpatrick 2001)
70
which cannot be taken as final proof. Thus, the occasional ChR2-tdTomato expression
seen in detrusor smooth muscle cells might reflect true activation of the ChAT promotor,
but it also might due to leaky expression. In either case, this has to be considered when
interpreting the functional data, and this will be further worked out in chapter 4.2.4.
There is also evidence for inefficient Cre-expression in non-neuronal cholinergic cells in
our mouse model. ChAT-immunolabeling revealed cholinergic epithelial cells, most
probably representing cholinergic tuft (=brush) cells (Schütz et al. 2015), that did not
express ChR2-tdTomato. Similar cholinergic chemosensory cells also occur in the
tracheal and laryngeal epithelium (Krasteva et al. 2011, Krasteva et al. 2015) but did also
not show up in ChR2-tdTomato fluorescence. It thus appears to be likely that Cre-driven
recombination was particularly ineffective in this cell type. In either case, this had no
impact on the functional part of this study since, in the urinary tract, such cells are
restricted to the urethra but are absent from the urinary bladder (Deckmann et al. 2014).
With respect to nerve fibers, fluorescence microscopy of airways, digestive tract and
urinary bladder revealed a dense innervation with ChR2-tdTomato-fluorescent fibers that
matched in distribution and extent that what is known for cholinergic nerve fibers
(Schäfer et al. 1988). Immunoreactivities to key proteins for cholinergic signaling, i.e.
ChAT and VAChT (the latter investigated in the bladder only), colocalized with native
ChR2-tdTomato-fluorescence. Although there was extensive colocalization, these signals
did not always correlate 1:1. There are two likely reasons for this slight mismatch: 1)
Incomplete efficiency of expression, as already discussed. Notably, this has also recently
been described for another genetically based model to visualize ChAT expression (Brown
et al. 2018). 2) The three proteins detected in fluorescence microscopy, i.e. the ChR2-
tdTomato fusion protein, ChAT and VAChT, all have different subcellular distribution.
ChR2 is a membrane protein, ChAT is a cytoplasmatic protein, and VAChT is a
membrane protein of intracellular vesicles. This different subcellular localization will
lead to incongruencies in the distribution of fluorescent signals. In case of very small (<1
µm) nerve fibers this might not drastically change the fluorescence pattern. In the case of
neuronal cell bodies, however, this was clearly visible.
Particularly important, the catecholamine-synthesizing enzyme TH was not detected in
ChR2-tdTomato-fluorescent fibers, so that stimulation of noradrenergic sympathetic
fibers did not occur in our functional experiments. Colocalization with the neuropeptide
SP, a member of the tachykinin family, was observed in the muscle layer of the
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duodenum, but neither in the airways nor in the urinary bladder. This differential pattern
of colocalization nicely mirrors previous immunohistochemical and functional studies
demonstrating SP as a cotransmitter of ACh in enteric motoneurons (Qu et al. 2008),
whereas it is contained within non-cholinergic, peptidergic sensory fibers in the airways
(Xiao and Wu 2012, Tränkner et al. 2014) and urinary bladder (Moss et al. 1990, Mitsui
and Hashitani 2013).
Altogether, the histological analysis of the urinary bladder and other peripheral organs
validated the suitability of the newly generated mouse model for optogenetic studies of
autonomic cholinergic neurons.
4.2 Contractile activity of the detrusor muscle of mice in
response to exogenous stimuli
4.2.1 LED stimulation evokes detrusor contraction specifically in ChAT-
ChR2 mice
To our knowledge, this is the first report providing data on organ bath experiments in
mice with the expression of ChR2 in peripheral cholinergic nerve fibers. The control
group of mice, expressing the only green fluorescent protein in cholinergic nerve fibers,
was taken for comparison of the outcomes and exclusion of experimental side effects.
Our results demonstrated that the application of LED stimuli with different impulses leads
to the contraction of the urinary bladder only in ChAT-ChR2 mice. The response to EFS
in our experiments was comparable for both groups, so we can conclude that the
additional expression of ChR2 did not interfere with the functional properties of the
cholinergic innervation of the urinary bladder.
To test our preliminary outcome about the unique specificity of the LED stimuli to the
ChAT-ChR2 mouse strain, we used the same protocol for organ bath experiments as in
control ChAT-GFP mice. The thermal effect in organ bath experiments should not be
underestimated. Burdyga and Wray described in their experiments that warming of the
tissue during organ bath experiments increases phasic contraction of the smooth muscle
of the rat ureter. This effect was caused by prolongation of the Ca2+ transient that allows
the myofilament to come closer to equilibrium with Ca2+ and increases force production
(Burdyga and Wray 2002). In our experiments, however, the response to LED stimulation
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was specific only for ChAT-ChR2 mice, and herewith, we could exclude a side effect,
which might occur through thermal influence.
In our investigations, we observed a frequency-dependent increase in force in EFS, but
not in our LED stimulation protocol. Applying pulsed LED stimuli at 32 Hz, we examined
a decrease of contraction of the detrusor muscle. Meanwhile, EFS, on its turn led to a
proportional increase of contractions as the frequency of stimuli raised. One likely
explanation is that the pulse duration during the EFS was kept constant, whereas in LED
protocol the pulse duration was adapted to equal on-off periods. In addition, other studies
revealed inhibition of neuronal activity during high-frequency optical stimulation of
ChR2-expressing neurons in the mouse brain (Witten et al. 2010, Anikeeva et al. 2012).
These authors supposed that in most cases inhibition was produced by excitation of
cholinergic or parvalbumin interneurons that have inhibitory effects on the neuronal fiber
activity. Since there are no interneurons known in the detrusor bladder, this effect is
unlikely to have occurred in our experiments. Liske and colleagues performed systematic
analysis to determine if the frequency-dependent stimulation of ChR2 could achieve both
excitation and inhibition. Their results demonstrated that the average force amplitude
during LED stimulation decreased significantly with increasing light pulse frequency in
Thy1-ChR2-EYFP mice (Liske et al. 2013).
4.2.2 Only a third of the contraction induced by cholinergic nerve fibers
is mediated via muscarinic cholinergic receptors
An atropine-resistant response of the urinary bladder to electrical stimulation was first
mentioned at the beginning of the 20th century (Langley 1911). Langley disclosed that
the electrical stimulation of the urinary bladder was still effective in causing contraction
after 10 mg of atropine sulfate. Hukinovic and colleagues observed that atropine, in the
concentration of 0.1 µg/ml, reduced the effect of electrical stimulation in the rat urinary
bladder by one third. They have reported that higher concentration of atropine had no
further effect on reduction of contractility of the bladder (Hukinovic et al. 1965). Later
studies also confirmed the resistance of the urinary bladder contraction to atropine
treatment. For example, Brading and Williams in the early 90s compared the contractile
responses of strips of rat and guinea-pig detrusor muscle to the effect of atropine
treatment. They observed that atropine at 0.5 µM concentration did not show an obvious
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effect either to guinea-pig nor rat detrusor muscle. However, an increased atropine
concentration (3 µM) led to a 25% reduction of the contraction in both animal models
(Brading and Williams 1990). Some other authors, for example, Elliot and colleagues,
detected a diminution of the maximum contractile response by half after treatment with
atropine the detrusor muscle of the rat (Elliot et al. 2000).
In the human bladder, atropine-resistant contraction is described 5 to 30 % in so-called
“normal” bladders (Sjögren et al. 1982, Luheshi and Zar 1990, Tagliani et al. 1997). In
1999, Bayliss and colleagues analyzed characteristics of atropine-resistant contraction in
the human detrusor. They concluded that humans with stable bladder (control group) do
not have an atropine-resistant contraction at any electrical stimulation frequency and the
group of patients undergoing transurethral prostate resection and urodynamically proved
bladder instability according to ICS definitions have a frequency-dependent atropine
resistance up to 20 % (Bayliss et al. 1999). Fry and colleagues published a detailed
characterization of atropine-resistant contraction due to bladder disorders in a large
number of human detrusor biopsies. They observed that patients with idiopathic detrusor
overactivity have higher atropine-resistance (23.0 %) than patients with neurogenic
detrusor overactivity (14.7 %) or bladder outlet obstruction (11.5 %). The results of the
control group – patients with a stable and unobstructed bladder - were comparable with
the study of Bayliss and colleagues and did not show atropine-resistant contraction (Fry
et al. 2011). Striking results were achieved by Johal and colleagues. They observed a
large proportion of atropine resistance in detrusor contraction from pediatric bladders
compared with adult bladders (Johal et al. 2014). This conclusion could explain why
many children are refractory to antimuscarinic therapy (Elmissiry et al. 2013).
We treated the detrusor muscle of ChAT-ChR2 mice with 2 µM atropine to block the
muscarinic acetylcholine receptors of the muscular tissue and observed that atropine
diminished the contractile force in organ bath in response to both LED stimulation and
EFS. Interestingly, the atropine-resistant detrusor contraction induced by LED was the
same for all frequencies and composed two-thirds of the pretreatment contraction. In
contrast, during EFS the diminution of contraction after atropine treatment was
frequency-dependent and was reduced by 5–21 %. In previous literature, we were not
able to find sufficient information about isolated activation of postsynaptic
parasympathetic neurons in the urinary bladder. Thus, we cannot truly compare our
results of pure optogenetic stimulation of cholinergic nerve fibers with LED and data
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obtained externally. Even so, in target-specific LED stimulation, reduction of contractility
demonstrated a stronger response to atropine than it was seen in EFS. The blockade that
we received by atropine in the EFS experiments was less than that reported in previous
studies (Brading and Williams 1990, Elliot et al. 2000). Such discrepancy between our
observations and the results of the previous studies can be explained by the duration of
the impulse, individual properties of the organ bath and concentration of atropine.
The efficiency of atropine treatment was validated in our experiments by application of
muscarine (10-5 M) to the organ bath, and this muscarine-induced contraction was fully
abrogated. Muscarine was chosen instead of ACh since the latter also activates nicotinic
receptors, and full blockade of the response to high doses of ACh requires both atropine
and a nicotinic receptor blocker such as hexamethonium (Chesher and Thorp 1965).
The activation of parasympathetic postganglionic nerves releases ACh, which serves as a
transmitter that mediates detrusor contraction via M2 and M3 subtypes of muscarinic
receptors (Hegde and Eglen 1999). However, our data demonstrated that when
cholinergic nerve fibers are selectively activated, a certain portion of the contraction is
atropine-resistant. This outcome led us to the assumption of the existence of an additional
transmitter or group of transmitters that are co-released besides ACh from cholinergic
nerve fibers in the detrusor.
4.2.3 A purinergic transmitter is co-released with ACh from cholinergic
nerve fibers in the detrusor muscle
The first evidence of non-cholinergic, non-adrenergic transmission in the detrusor was
demonstrated in the seventies of the last century by Ambache und Zar (Ambache and Zar
1970). In their experiments, they demonstrated that the mucosa-free detrusor muscle of
the guinea-pig bladder responds to electrical stimulation despite blockade of muscarinic
receptors. In 1978, Burnstock and colleagues postulated that the atropine-resistant
contraction in the guinea-pig bladder was triggered by ATP that is released from a
neuronal pool (Burnstock et al. 1978).
Later studies supported this hypothesis not only in guinea-pig bladder but also in many
other species, including pig, mouse, hamster, monkey, cat, and others (MacKenzie et al.
1982, Santicioli et al. 1986, Levin et al. 1990, Creed et al. 1994, Masuda et al. 1995, Pinna
et al. 1998). Creed and colleagues came to the conclusion that two transmitters are
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released from excitatory nerves due to a comparison of the reduction of the detrusor
contraction during the EFS to different blocker cocktails. The results demonstrated that a
cocktail of atropine and suramin reduces the contraction of rabbit’s, guinea-pig’s and
monkey’s (baboon or rhesus) detrusor more that atropine alone (Creed et al. 1994). Levin
and his colleagues extensively studied lower urinary tract function in both the cat and the
rabbit (Levin et al. 1980, Levin et al. 1981, Levin et al. 1986). They proposed the presence
of purinergic nerves, which release ATP during the activation of cholinergic nerve fibers
in the bladder. This conclusion was supported by the fact that ATP stimulates a
contraction in the rabbit detrusor that has the same magnitude as the atropine-resistant
contraction in EFS (Levin et al. 1990). The study of Pinna and colleagues provided clear
evidence that the purinergic neurotransmitter ATP plays a key role in detrusor
contraction. In their experiments in the hamster bladder, they were able to inhibit the EFS-
induced detrusor contraction by atropine together with suramin by 90 % (Pinna et al.
1998).
ATP is now recognized as a fast neurotransmitter released from nerve terminals. It has
extracellular action via the ionotropic P2X receptors, which are ligand-gated cation
channels, and metabotropic P2Y receptors, which are G protein-coupled receptors
(Kennedy et al. 2013, Khakh et al. 2001). At this point, it should be discussed that ATP
is not the only known purinergic ligand (Hoyle et al. 1990). The P2-purinoreceptors are
also activated by adenosine 5-diphosphate (ADP). An adenine-dinucleotides that acts as
a neurotransmitter is β-nicotinamide adenine dinucleotide (β-NAD) (Hoyle et al. 1990,
Mutafova-Yambolieva et al. 2007). Stone was the pioneer author who described β-NAD-
induced prejunctional inhibition of sympathetic neuromuscular transmission in the vas
deferens of the rat (Stone 1981). Stone observed that β-NAD inhibits the contractile
activity of the vas deferens of the rat by 40-42 %. Later, Burnstock and Hoyle concluded
that β-NAD acts largely indirectly as P1–purinoreceptor agonist following its breakdown
to adenosine by ectoenzymes. The results of their experiments demonstrated that β-NAD
possesses concentration-dependent relaxations in the carbachol-contracted taenia coli.
Also, they detected adenosine in all samples with β-NAD treatment. These results imply
that β-NAD is broken down to adenosine or that β-NAD induces the release of adenosine
from tissue (Burnstock and Hoyle 1985). Further, the studies of Smyth and colleagues
identified the nerve-evoked release of β-NAD and its metabolic product cyclic adenosine
5’-diphosphoribose (cADPR) and adenosine 5’-diphosphoribose (ADPR) in vascular and
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non-vascular smooth muscle preparations. These nucleotides probably regulate the
release of norepinephrine at the vascular neuroeffector junction (Smyth et al. 2004). The
same group of scientists observed the release of β-NAD by stimulation of postganglionic
nerve terminals in the human detrusor smooth muscle in a TTX-sensitive manner. This
observation led the authors to the conclusion that β-NAD can be a novel player in the
neural control of the human bladder (Breen et al. 2006). But the release of β-NAD in this
study was unaffected by guanethidine, and increased by capsaicin, these support the
assumption that the β-NAD might be released from sensory nerves (Breen et al. 2006).
This leads us to the conclusion that the contraction induced by the LED in bladders of
ChR2 mice is more likely transmitted through ATP rather than β-NAD.
We used inhibitors of P2-purinergic receptors - suramin and PPADS - to block a potential
purinergic component resulting from selective stimulation of cholinergic nerve fibers in
the detrusor muscle. Suramin is a potent inhibitor of a Na+-K+-ATPase at an intracellular
site, by interfering with the binding of ATP (Fortes et al. 1973). ATP acts as a transmitter
and can cause either contraction or relaxation by the activation of P2X- or P2Y-
purinoreceptors, respectively (Burnstock and Kennedy 1985, Dunn and Blakeley 1988).
The first evidence of a reversible antagonistic effect of suramin on P2-purinoreceptors
was obtained in mouse vas deferens by Dunn and Blakeley (Dunn and Blakeley 1988).
They concluded that suramin can effectively inhibit the contraction of the vas deference
provoked by α,β-methylene ATP. Later, Hoyle and colleagues showed a non-competitive
antagonism of suramin to α,β-methylene ATP in detrusor strips of the guinea pig (Hoyle
et al. 1990). Interestingly, the same study revealed concentration-dependent differential
effects of suramin in the guinea-pig urinary bladder. The authors reported that suramin at
a concentration of 1 µM increased the amplitude of contraction at low frequencies of EFS.
At a concentration of 100 µM, it caused an inhibition of the contractile response only at
frequencies of 4 to 32 Hz. The strongest inhibitory effect was observed at a concentration
of 1 mM (Hoyle et al. 1990).
Lambrecht and colleagues were the first who reported PPADS as a P2X antagonist
(Lambrecht et al. 1992). The results of their study demonstrated that PPADS selectively
inhibits purinoreceptor-mediated response in the rabbit vas deferens. The same effect of
PPADS was also shown in the rabbit urinary bladder (Ziganshin et al. 1993). Ziganshin
and colleagues also described a concentration-dependent effect of PPADS in the rabbit
detrusor muscle by EFS. At a concentration of 1 µM, PPADS inhibits a contraction at
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lower frequencies. Between 10 and 30 µM, the inhibition of detrusor contraction was
significant at all frequencies. In 1998, Pinna and colleagues compared the inhibitory
effects of suramin and PPADS to the hamster urinary bladder. The results showed that
the suramin at a concentration of 10-4 M and PPADS at 10-4 M give a similar degree of
inhibition (Pinna et al. 1998).
Based on this data, we used a combination of PPADS and suramin because the literature
review suggested that the inhibition of EFS-induced contractions by the mixture is
slightly higher than that when drugs were applied separately (Undi et al. 2006, Shiina et
al. 2007). Undi and colleagues described a stronger inhibition (approximately 70%) of
contraction of human ileal tissue by both PPADS (50 µM) and suramin (100 µM) rather
than when a single inhibitor was used (Undi et al. 2006). Similar results were also
obtained by Shiina and colleagues. The contractile activity of the rectum of Japanese
quails was strongly inhibited by combined application of suramin (50 µM) and PPADS
(10 µM) (Shiina et al. 2007).
After the treatment of the urinary bladder with suramin and PPADS, contraction induced
by LED was reduced up to two thirds in detrusor preparations taken from ChAT-ChR2
mice. These results serve as direct evidence of cotransmission of a P2X agonist (most
likely ATP) and ACh in cholinergic nerve fibers in the urinary bladder of the mouse. In
contrast to LED stimulation, the EFS-induced contraction was reduced by less than one
third after application of suramin and PPADS. This differential effect reflects that EFS
has a lack of target-specificity to cholinergic nerve stimulation of the detrusor and excites
additional nerve fiber populations. It can be deduced from these findings that these
additional, non-cholinergic fibers also contribute to neurally evoked detrusor contraction
and that this component is largely non-purinergic. Comparing our EFS data with that of
earlier EFS studies showed that the results reported herein are mostly consistent with our
results achieved during the inhibition of electrical stimulated detrusor contraction with
suramin and PPADS (Creed et al. 1994, Tong et al. 1997, Knight and Burnstock 2004).
Still, Kennedy and coworkers described that suramin and PPADS suppressed the
contraction slightly more in comparison to the previous studies. The peak response was
inhibited by 50-60 % (Kennedy 2015).
The present study is the first to provide direct evidence for cholinergic-purinergic
cotransmission in the detrusor since tools for selective activation of cholinergic nerve
fibers had not been available earlier. Also, selective disruption of postganglionic
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parasympathetic cholinergic fibers, equivalent to chemical denervation of postganglionic
sympathetic noradrenergic nerves with sympatholytics such as guanethidine or 6-
hydroxydopamine, had not been achieving yet. Still, there is strong indirect evidence for
cotransmission in postganglionic parasympathetic neurons at other organs, specifically
salivary glands. Lundberg and colleagues observed that ACh and VIP are released from
the parasympathetic nerve terminals in cat salivary glands. They described that during
low-frequency stimulation, ACh is released and caused an increase in salivary secretion.
VIP is released at high stimulation frequencies and causes vasodilatation of blood vessels.
Also, they proposed that VIP acts as a neuromodulator and increases both the
postjunctional effect of ACh in salivary secretion and the release of ACh from nerve
varicosities via prejunctional receptors (Lundberg 1981). One of the first proposals that
ATP and ACh might be cotransmitters in cholinergic nerves supplying the bladder was
put forward by Hoyes and colleagues. They observed that the nerve terminals, supplying
the smooth muscle of the bladder, have small dense-cored vesicles that contain a second
transmitter, which is co-released with ACh during the activation of parasympathetic
postganglionic nerve fibers (Hoyes et al. 1975). Further indirect evidence for purinergic-
cholinergic cotransmission was reported by Mackenzie and coworkers. The authors
observed that guinea-pig detrusor strips respond to EFS with a twitch-like rest contraction
in the presence of atropine and guanethidine, but this contraction was abolished in the
presence of botulinum toxin (Mackenzie et al. 1982). It was assumed that botulinum toxin
specifically inhibits transmitter release from cholinergic nerve terminals (Carpenter
1978). Thus, Mackenzie and his coworkers suggested that the parasympathetic neurons
supplying the smooth muscle of guinea-pig urinary bladder co-release in ACh with ATP
or polypeptides. (Mackenzie et al. 1982). It is now clear, however, that botulinum toxin
also inhibits to some extent noradrenergic postganglionic sympathetic nerve endings and
peripheral terminals of sensory neurons (Rosetto 2018). Indeed, botulinum toxin is now
used for the treatment of pain syndromes (Chiu et al. 2016, Park and Park 2017). Thus,
botulinum toxin cannot be taken as a tool to selectively deactivate cholinergic neurons.
Cotransmission of ATP and noradrenaline is well studied in the sympathetic nervous
system (Burnstock 2013). The first evidence that ATP is released from sympathetic nerve
fibers was the demonstration that stimulation of sympathetic nerves led to release of
tritium from taenia coli preincubated in [3H] adenosine. This converted to [3H]ATP (Su
et al. 1971). In animal models, many pioneer experiments establishing sympathetic
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cotransmission were performed in the vas deferens because of its highly dense innervation
with sympathetic nerve fibers, mostly arising from the hypogastric ganglion (Hukinovic
et al. 1961, Burnstock and Verkhratsky 2010). For example, Todorov and colleagues used
high-performance liquid chromatography to monitor the release of ATP and
noradrenaline (NA) during the stimulation of sympathetic nerves innervating the guinea-
pig vas deferens. They discovered that the peak of NA release was at 40 s after the
beginning of stimulation and remained constant, whereas the peak of ATP release was at
20 s after the start of stimulation and decreased despite ongoing contraction. These results
were consistent with the phasic nature of the purinergic component that was described by
Westfall and coworkers (Todorov et al. 1996, Westfall et al. 1978). The group of Westfall
was the first to demonstrate that ATP provokes fast contraction of the vas deferens as a
cotransmitter with NA released from sympathetic nerves producing a slower contraction.
Later studies showed that the destruction of sympathetic nerves with 6-hydroxydopamine
led to abolishing of the purinergic response, strongly suggesting that ATP was released
from sympathetic nerve fibers and not separately from purinergic nerves (Kirkpatrick and
Burnstock 1987). A more recent paper of Bank and coworkers described a purinergic
component in the human vas deferens. This study demonstrated that the human vas
deferens contracts in response to purinergic agonists and the P2 antagonist PPADS reduce
EFS-evoked contraction up to 40 % (Banks et al. 2006).
Thus, depending on organ system, a P2 receptor agonist, most likely ATP, can serve as a
cotransmitter both in noradrenergic sympathetic neurons, as demonstrated earlier, and in
cholinergic parasympathetic neurons, as validated in the present study for the mouse
urinary bladder.
4.2.4 Potential sources of residual LED-induced detrusor contraction
under combined muscarinic-purinergic receptor blockade
Our results demonstrate that approximately 20% of the LED-induced contraction
remained under combined cholinergic muscarinic and purinergic inhibition. This was not
due to a non-specific effect of LED illumination on detrusor activity, as LED had no
effect in controls expressing a fluorescent protein (eGFP), but not ChR2, in cholinergic
nerve fibers. There are several possible explanations for this residual contractile effect
(Fig 4.1):
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1. Direct and indirect involvement of nicotinic cholinergic receptors on the detrusor
contraction
2. Co-release of another, non-purinergic transmitter
3. Ectopic expression of ChR2
Figure 4.1 Schematic showing of possible pathways explaining the residual LED-induced
contraction of detrusor after the muscarinic, purinergic blocker cocktail. 1a. Direct
activation of nAChR through ACh; 1b. Indirect activation of nAChR; 2. Co-release of
another, non-purinergic transmitter; 3. Ectopic expression of ChR2
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Direct and indirect involvement of nicotinic cholinergic receptors on detrusor
contraction
It is established that the main mechanism of nerve-evoked urinary bladder contraction
involves the release of ACh acting on muscarinic receptors and of ATP acting on
purinergic receptors (Burnstock 2014). Nicotinic receptors are not thought to directly
mediate contraction of the normal bladder muscle (Gomez-Amaya et al. 2015) but still,
contribute to contraction evoked by ACh given in high doses in organ bath experiments
(Chesher and Thorp 1965). It is known that autonomic ganglia, including bladder
intramural parasympathetic ganglion cells, express numerous types of nicotinic receptors.
Deficiency of α3, β2 and β4 subunits of nicotinic acetylcholine receptor (nAChR) in mice
leads to dysfunction of the bladder (De Biasi et al. 2000). However, there is insufficient
information on the mechanism of how nAChRs induces bladder smooth muscle
contraction (Fincan et al. 2016). Previously, it was discussed that ACh facilitates its own
release through the effect on prejunctional nicotinic receptors (Vizi et al. 1989).
Furthermore, Vizi and colleagues observed that atropine, a muscarinic blocker, had no
effect on the release of ACh evoked by physostigmine at the skeletal neuromuscular
junction (Vizi et al. 1989). Another evidence of a crucial role of nAChR in the regulation
of bladder function was demonstrated by Gallagher and colleagues. They reported that
neuronal nAChRs mediate fast synaptic transmission between preganglionic and
postganglionic bladder neurons yielding detrusor muscle contraction (Gallagher et al.
1982).
A recent publication of Gomez-Amaya and coworkers demonstrate the expression of α1
nicotinic receptor subunits on the smooth muscle in the mongrel hound dog urinary
bladder reinnervated by somatomotor fibers. They observed that, under this experimental
condition, activation of this receptor leads to a more rapid increase in bladder pressure
than the activation of muscarinic receptors (Gomez-Amaya et al. 2015). Another evidence
of direct participation of nicotinic receptors in detrusor contraction was published by
Fincan and colleagues. They observed that nicotine significantly enhanced EFS induced
contractile responses, and these responses were largely inhibited with mecamylamine
(Fincan et al. 2016). Earlier, Vural and coworkers published interesting results showing
that nicotine, a non-specific nAChR agonist, increased the contractile responses of the
rabbit urinary bladder strips elicited by the EFS in a dose-dependent manner (Vural et al.
2007).
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On the other hand, nAChR might indirectly increase the release of various
neurotransmitters following nerve stimulation in different tissues (Todorov et al. 1991,
Yokotani et al. 2001). Todorov and colleagues verified the presence of prejunctional
nicotinic receptors on noradrenergic nerve terminals in the vas deferens of the guinea-
pig. They observed that nicotinic receptor agonists promoted the release of [3H]-NA and
this stimulation-evoked release was reduced by hexamethonium (Todorov et al. 1991).
Vural and colleagues supposed that nicotine may increase the EFS-induced contractile
response, possibly by facilitating co-neurotransmitter release from nerve terminals via
activation of nAChRs in rabbit bladder.  According to their experiments, neither nitric
oxide nor prostaglandins are involved in this process, since neither N-nitro-L-arginine
methyl ester hydrochloride nor indomethacin, a non-selective cyclooxygenase inhibitor,
affected the nicotine-induced contraction. Additionally, they proposed that nicotine
evokes, by acting on the neuronal nAChRs, the co-release of ACh and ATP from
postsynaptic parasympathetic nerve terminals in the rabbit bladder. This proposal arose
from the observation of amplification of EFS-induced contractile responses after
application of nicotine in the presence of either atropine or α,β-methylene ATP. However,
hexamethonium, a nicotinic blocker, did not show any effect on stimulation in the absence
of nicotine, indicating that nAChRs are not involved in physiological activation of the
bladder (Vural et al. 2007).
We here addressed the potential influence of nAChRs on optogenetically induced
detrusor contraction in ChAT-ChR2 bladders by applying mecamylamine, a general
nAChR antagonist. Our results demonstrate that mecamylamine did not affect the LED-
induced contractile responses resulting from selective stimulation of cholinergic nerve
fibers. Thus, the residual contraction seen after combined muscarinic and purinergic
receptor blockade is not caused by ACh acting upon nAChR.
Co-release of another, non-purinergic transmitter
Another explanation for the residual contraction of LED-induced cholinergic contraction
of the detrusor after cholinergic-purinergic blocker cocktail might be another
cotransmitter that is released from cholinergic nerve fibers, for example, peptides (Hoyes
et al. 1975). Meini and Maggi provided the first evidence for the existence of a capsaicin-
sensitive component in the atropine-resistant non-adrenergic non-cholinergic contraction
induced by EFS in the rat urinary bladder. This effect, however, was ascribed to
tachykinin release from sensory nerve terminals (Meini and Maggi 1994) and, hence, does
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not represent peptidergic cotransmission from cholinergic neurons. Benko and colleagues
also observed a remaining EFS-induced contraction after atropine, suramin, and PPADS
pretreatment, but this was independent from capsaicin-sensitive (i.e. peptidergic sensory)
nerve endings and the transmitter background remained unclear. However, the same study
revealed that capsaicin-induced contraction has myogenic, but not neurogenic origin due
to the resistance of capsaicin-induced contraction to tetrodotoxin and ω-conotoxin GVIA
(Benko et al. 2003). Other early studies negated the possibility of cholinergic-peptidergic
cotransmission in the detrusor, due to the lack of the similarity of mimicry of
neuropeptide-stimulated contraction to the fast atropine-resistant contraction of the
detrusor (Mackenzie and Burnstock 1984, Callahan and Creed 1986). Collectively, there
is currently no other transmitter being identified that might serve as an additional
cotransmitter in cholinergic-purinergic bladder innervation.
Ectopic expression of ChR2
It finally has to be considered that ChR2 has been ectopically expressed outside
cholinergic nerve fibers. Indeed, we observed occasional tdTomato expression in patches
of lung alveolar cells, very rarely in skeletal muscle fibers in larynx and tongue, and,
although not regularly and to a varying degree from animal to animal, in detrusor smooth
muscle cells. Then, contraction might be induced by the activation of ChR2 in the smooth
muscle cell membrane through LED stimulation. Park and colleagues have generated a
ChR2 mouse line that expresses ChR2 in the detrusor smooth muscle. In this model, they
assessed the depolarization, induced by ChR2 activation in the isolated detrusor after
LED stimuli. The results show that illumination at 473 nm immediately induces an inward
current in the smooth muscle cells with an initial peak followed by quick relaxation to a
plateau level (Park et al. 2017). Hence, this interindividual variable and minor ectopic
expression of ChR2 in smooth muscle cells in our experimental model may well explain
the small residual contractile response seen after combined muscarinic and purinergic
receptor blockade.
4.3 The future role of optogenetics in the understanding of the
lower urinary tract
LUT possesses an essential role in storing and voiding of urine. Highly complex neural
circuits involving supraspinal, spinal and peripheral mechanisms, coordinate the coaction
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of smooth and striated muscle, hereby enabling the functioning process of micturition
(Fowler et al. 2008). Often, storage disorder component of LUT is associated with
overactive bladder, defined symptomatically as the OAB, or urodynamically as detrusor
overactivity (Abrams et al. 2003). Existing pharmacological treatment might have initial
good response rates but are not effective in all patients (Andersson 2016). The
mechanisms of effect of the antimuscarinic therapy, that improve the symptoms, and
therefore are considered to be the first-line treatment of OAB, remain undiscovered. The
common opinion that antimuscarinic drugs may reduce the ability of the detrusor to
contraction via the blockage of the muscarinic receptors of the efferent nerve fibers of the
detrusor muscle is still under debate (Yamaguchi 2010). Further studies are needed in the
future, to a better understanding of the function of peripheral neuronal circuits in the
bladder sensation and contraction, before the initiation of the targeted pharmacological
therapy. Our study is the first describing the successful application of optogenetics in the
neuromodulation of isolated cholinergic neural circuits of postganglionic
parasympathetic neurons in the detrusor smooth muscle. The application of optogenetics
is a promising new field in the research of neurologic diseases and may be extended to
other cell populations contributing to the regulation of micturition. Up to date,
optogenetic investigations of micturition centers and the central peripheral neural circuits,
controlling the lower urinary tract, are lacking. Application of the optogenetics will help
to modulate the mechanisms that underlie sensory transduction of pelvic and hypogastric
bladder afferents or help to understand the role of sub-urothelial sensory processing in IC
and in the modulation of the spontaneous activity of the detrusor smooth muscle. Another
field where optogenetic could have clinical relevance is the treatment of OAB or atone
bladder instead of electrical sacral neuromodulation. By the application of different
opsins in the urinary bladder, control of the contractile behavior may be achieved through
the on-off switch of the LED stimuli (Parker et al. 2017). All of these will provide new
opportunities leading to the development of novel treatments for bladder dysfunctions.
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5 Summary
Parasympathetic nerve fibers control the contraction of the bladder musculature. Only a
third of the contraction induced by their general activation through EFS is inhibited by
antagonists of muscarinic ACh receptors. The remaining contraction is predominantly
mediated via purinergic receptors. However, it is unclear whether purinergic ligands are
released together with ACh from the same nerve fibers, or from a separate fiber
population. We have clarified this question in a transgenic animal model with an
optogenetic approach. Here, a light-sensitive channel, ChR2, is expressed in cholinergic
neurons so that they can be selectively excited by light at a wavelength of 460 nm.
A mouse line expressing a ChR2-dtTomato fusion protein under control of the ChAT
promotor was generated by crossing the strains B6N.129S6(B6)-Chattm2(cre)Lowl/J and
B6;129-Gt(ROSA)26Sortm1(CAG-COP4*E123T*H134R,-tdTomato)Gfng/J. ChR2-dtTomato expression
in the urinary bladder and reference organs was characterized by immunofluorescence
microscopy. Detrusor contractions were measured in an organ bath in response to EFS
and LED (460 nm) stimulation. As a control group, we used a ChAT-eGFP mouse strain
that does not express ChR2.
Immunofluorescence microscopy revealed expression of the ChR2-dtTomato fusion
protein in cholinergic (ChAT- and VAChT-positive), but not other (noradrenergic,
peptidergic sensory) nerve fibers in the urinary bladder and other peripheral organs (e.g.
airways and duodenum). EFS led to a frequency-dependent contraction in all strains. LED
stimulation evoked a contraction of the urinary bladder only in the ChR2-expressing
mouse strain so that thermal effects were excluded. Atropine completely inhibited the
muscarine-induced contraction of the bladder but reduced the LED-evoked contraction of
the detrusor only by 35%. The application of purinergic receptors antagonists, suramin
and PPADS, reduced the LED-induced contraction of the detrusor by 60%. Even after
combined cholinergic muscarinic and purinergic inhibition, approximately 20% of the
LED-induced contraction remained.
For the first time, this optogenetic approach proves cholinergic-purinergic cotransmission
in the detrusor by releasing at least two transmitters from the same nerve fiber. The
remaining contraction after combined blockade of muscarinic cholinergic and purinergic
(P2) receptors may result from a minor ectopic expression of ChR2 in the detrusor muscle
or another transmitter system, which can be clarified by further investigations using this
model.
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6 Zusammenfassung
Parasympathische Nervenfasern steuern die Detrusorkontraktion. Eine vollständige Inhibition der
cholinergen Übertragung hemmt die durch generelle Nervenstimulation (elektrische
Feldstimulation) induzierte Kontraktion nur zu einem Drittel. Die verbleibende Kontraktion wird
vorwiegend über purinerge Rezeptoren vermittelt. Unklar ist jedoch, ob die purinergen Liganden
gemeinsam mit ACh aus den gleichen Nervenfasern freigesetzt werden, oder aus einer separaten
Faserpopulation. Wir haben diese Frage in einem transgenen Tiermodell mit optogenetischem
Ansatz geklärt. Hierbei wird ein lichtsensitiver Kanal, ChR2, in cholinergen Neuronen exprimiert,
sodass diese selektiv durch Licht einer Wellenlänge von 460 nm erregt werden können.
Eine Mauslinie, die ein ChR2-tdTomato-Fusionsprotein unter der Kontrolle des ChAT-Promotors
exprimiert, wurde durch Kreuzung der Stämme B6N.129S6(B6)-Chattm2(cre)Lowl/J und B6;129-
Gt(ROSA)26Sortm1(CAG-COP4*E123T*H134R,-tdTomato)Gfng/J generiert. Die ChR2-dtTomato Expression
wurde in der Harnblase und Referenzorganen durch (Immun)fluoreszenzmikroskopie
charakterisiert. Detrusor-Kontraktionen wurden im Organbad nach EFS und Lichtstimulation
(LED, 460 nm) gemessen. Als Kontrollgruppe wurde ein ChAT-eGFP-Mausstamm ohne ChR2-
Expression verwendet.
Die Immunfluoreszenz zeigte eine Expression des ChR2-tdTomato-Fusionsproteins in
cholinergen (ChAT- und VAChT-positiv), aber nicht anderen (nordrenergen, peptiderg-
sensorischen) Nervenfasern in der Harnblase und anderen peripheren Organen (z.B. Atemwege,
Duodenum). Eine elektrische Stimulation aller Fasern führte in beiden Mausstämmen zu einer
frequenzabhängigen Kontraktion. Die optische Stimulation durch LED-Lichtfaser kontrahierte
ausschließlich ChR2-exprimierende Blasen, so dass thermische Effekte ausgeschlossen werden
konnten. Atropin inhibierte vollständig die durch Muskarinzugabe induzierte Kontraktion, führte
aber nur zu einer Verminderung der LED-evozierten Kontraktion um 35 %. Die gemeinsame
Zugabe von Antagonisten purinerger Rezeptoren (Suramin und PPADS) reduzierte den LED-
Effekt um 60 %. Auch nach gleichzeitiger Gabe von Atropin, Suramin und PPADS verblieb ein
Resteffekt von 20 %.
Dieser optogenetische Ansatz weist erstmals eine cholinerg-purinerge Kotransmission im
Detrusor durch Freisetzung zumindest zweier kleinmolekularer Transmitter aus der gleichen
Nervenfaser nach. Die verbleibende Kontraktion nach Blockade cholinerger muskarinischer und
purinerger (P2) Rezeptoren kann durch eine geringe ektope Expression des ChR2 in einzelnen
glatten Muskelfasern oder auch durch ein weiteres Transmittersystem hervorgerufen werden, was
durch weiterführende Untersuchungen in diesem Modell geklärt werden kann.
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